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Referat (Abstract): 
 
Clinical findings have linked multiple pathologies to Alzheimer's disease (AD), particularly 
associated with the vasculature. Coexistence worsenes dementia, the clinical hallmark of the 
disease, as compared to pure AD. One general common denominator of these associated 
pathologies, such as stroke, is the presence of hypoxic tissue condtions. It was asked, whether 
there exists a mutual, causal interaction between hypoxia and AD pathology, that could 
explain the clinical observations. Alternatively, the worsened clinical state of multiple brain 
pathologies could "simply" be the consequence of multimorbidity, i.e. accumulated disease 
load, without any causal interaction between the constituents. 
The experimental results from a murine model of AD demonstrate, that long- term exposure 
to hypoxia significantly reduces the number of microglia. Thus the microglia function to 
confront A!- protein plaques, a hallmark in AD pathology, is compromized. The A!- 
quantity, however, is not affected. On the other hand, A!- quality shows an increased trend 
towards oligomer- formation. A variety of possible explanations for these phenomena are 
presented. Summarizing, no significant evidence was found for a causal link between hypoxia 
and A!- protein depositions in AD. 
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 1 
Introduction 
 
1. Alzheimer’s Disease 
Cognitive decline with age has long been recognized as an issue in human society, even being 
a problem to be addressed in lawmaking as early as 500 B.C. by Solon, a Greek judge. But for 
long, it was considered a routine part of the aging process, with Plato and Aristotle stating that 
old age and mental failure were inseparable. Pythagoras reckoned it fortunate that few people 
arrive at such an advanced age (Berchtold et al., 1998). Since then, things have changed. In 
1907 Alois Alzheimer published a case report that, in line with his fellow investigators at the 
time, started to see the observed condition of his patient as a disease, rather than an 
unfortunate property of old age (Alzheimer, 1907). This was a true turning point as cognitive 
impairment was beginning to be considered pathological rather than physiological and thus 
inevitable. However, roughly 100 years of investigation in the field have not yielded 
satisfying results yet, neither for treatment nor for cure. Nowadays, this issue gains increasing 
importance due to a rising life expectancy in the Western world. 
  
1.1 Clinical Appearance 
Alzheimer’s Disease (AD) is a neurodegenerative disease of the elderly, both progressive and 
fatal. There is however a rare form of the disease (early- onset AD) of particular genetic 
background which places the disease onset earlier in life. Amongst the most common clinical 
features of AD are amnesic memory impairment, language deterioration and visuo- spatial 
deficits. In short, AD constitutes one possible pathology that eventually causes dementia, 
which differs from the first in that it is a clinical finding. In later phases motor and sensory 
abnormalities, gait disturbances and seizures do occur. Patients show behavioural alterations 
and experience a progressive impairment of daily living (Cummings, 2004).  
Two forms of AD are to be distinguished: sporadic (late- onset) AD and early- onset AD, a 
subcategory of which is familial AD (Fig. I01). Early- and late- onset refer to before and after 
the age of 65 years, respectively. By prevalence, late- onset AD is 10- 20 times more common 
than early onset AD (Mayeux, 2010). Familial AD accounts for about 50% of all early- onset 
AD cases. The term "familial" refers to the fact, that affected individuals develop the disease 
due to genetic predisposition. About why the other 50% develop the disease earlier than usual 
little is known (Mayeux, 2010). 
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Fig. I01: Different forms of AD and their relative prevalence. 
 
1.2 Epidemiology  
AD has grown into a mayor public health issue as life expectancy rises constantly in 
developed countries over the last 50 years. The number of affected individuals increases with 
the progression of age, with prevalence roughly doubling every five years after 60 
(Cummings, 2004). The following figure (Fig. I02) illustrates this for individuals from a 
general population in the West (WHO, http://www.searo.who.int). 
 
 
Fig. I02: According to statistical data from the World Health Organisation (WHO), the AD prevalence increases 
dramatically with age, doubling every five years from 60 years onwards. 
 
In the US, out of 300 million citizens (U.S. Census Bureau, Report 2000), 5.3 million live 
with AD, which makes a 1.7% of the total population. Every 70 seconds somebody develops 
AD, the disease ranks 7th as cause of death, and 148 billion dollars are spent annually on 
medical care for AD patients and those with other dementias, which equals 1% of the gross 
domestic product (GDP) (CIA, World fact book). While cancer therapy evolves and offers 
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cures to a variety of tumours, no AD case has been cured since its discovery over 100 years 
ago. Effective symptomatic treatments are also still on the wait. 
 
1.3 Pathophysiology 
Histological features of patients’ brain samples include the accumulation of the self-
combinatory Amyloid- beta peptide (A!) in so called plaques, neuronal loss in selected brain 
regions and hyper-phosphorylated tau-protein in structures also referred to as tau- or 
neurofibrillary tangles (Blennow et al., 2006; Querfurth et al., 2010). 
Where does A! come from? Amyloid- beta peptide precursor protein (APP) is localized at the 
cellular membrane. It is cleaved in two major steps by proteases called secretases, leading to 
various products. Depending on which of the three ", ! and #-secretases consecutively 
cleaves APP, the process is amyloidogenic or not. To be more specific, if APP is cleaved first 
by !-secretase (also known as BACE, Beta- amyloid cleaving enzyme) and then by #-
secretase (a complex formed by various components), one of the products is A! (Chow et al., 
2010). The cleavage site of the #-secretase is not precise and results in A! protein variants 
with 39 to 43 amino acids, but mostly A!1-40 and A!1-42 with 40 and 42 amino acids, 
respectively. 
There is no consensus concerning the physiologic functions of APP and A!. It is however 
likely that they exist, since pathology cannot exist for pathology’s sake. APP is seen as a 
complex signalling center with multiple functions. Its main responsibility is believed to lie in 
the development of the nervous system and, through A! as signalling molecule, in synapse 
suppression (Kim et al., 2006). 
Efforts to understand the A! related pathology can be divided in two main fields: research 
that focuses on genetic modifications to study disease outcome, and investigations focusing 
on biochemical properties of the A! protein and interactions with itself and other players. 
 
1.3.1 Genetic base 
From the genetic viewpoint, AD is a heterogeneous disorder, with both familial and sporadic 
forms. After advanced age, a positive family history is the second most relevant risk factor for 
AD- like dementia (Selkoe et al., 2002b). APP is located on chromosome 21, which explains 
why patients with Down’s syndrome show signs of early-onset AD by a gene dosage effect. 
Furthermore, various missense mutations have been characterized in the APP gene. They 
result either in more efficient cleavage by !-secretase and thus higher levels of A!, or modify 
the ratio A!1-40 : A!1-42 in favour of the latter. Further mutations were localized to 
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presenilin1 and 2 (PSEN1/2) as part of the #-secretase complex, which results in a gain of 
function, modifying cleavage towards a selective surplus in the production of A!1-42 
(Selkoe, 2002a). One of the factors not involved in A! processing but genetically associated 
with AD is the $4 allele of apolipoprotein E (APOE) (Corder et al., 1993; Poirier et al., 1993). 
The risk for AD rises three-fold in heterozygous and 15-fold in homozygous individuals 
(Farrer, 1997). The allele affects the age of onset by ten years per copy (Meyer et al., 1998). 
The exact mechanism responsible for this observation is still under investigation. 
 
1.3.2 Protein base 
The most abundant forms of A!- protein are A!1-40 and A!1-42 with 40 and 42 amino acids, 
respectively, in a ratio 10:1 (Rauk, 2008), with A!1-40 as the predominant form found in 
cerebral blood vessels and A!1-42 mostly situated in the brain parenchyma (Glenner et al., 
1984; Kawarabayashi et al., 2001; Alonzo et al., 1998). An illustration of the APP is given in 
Fig I03. 
 
 
 
Fig. I03: Illustration adopted from Hardy et al. (Hardy et al., 2002); Shown is the processing of APP. Blue 
circles illustrate the amino acid sequence of APP. Red circles indicate mutations, known to cause familial AD. 
Scissors indicate cleavage sites for the various secretases and one protease. 
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Changes in the ratio in favour of the 42 amino acid isoform are associated with a more 
detrimental disease progression, which can in part be explained by the two additional 
hydrophobic amino acids in A!1-42. One of the properties of A! is its capability to assemble 
with its own kind, owing to a self-recognition site at A!12-23 (Tjernberg et al., 1997). It is 
consensus that neither the monomer (4.7 kDa), nor high molecular weight aggregates known 
as fibrils, are responsible for the neurotoxic effects associated with A!. Instead defects appear 
to be mediated by small oligomers, in the range of tetramers to 56 kDa (Lesne et al., 2006). 
To explain this further, the oligomer is a structure formed by aggregation of the monomer, 
self- assembling A!- protein. Various oligomers accumulate to even bigger structures called 
fibrils. The histologic correlate is the typical plaque structure found in AD brains. 
Summarizing, the above mentioned terms are referring to different grades of aggregation.  
Typical effects observed are neurotoxicity and the subsequent suppression of long- term 
potentiation (LTP) required in memory formation (Lambert et al., 1998). Furthermore, 
memory impairment through various other mechanisms has been observed (Rauk, 2008; 
Lesne et al., 2006). It is thought that after A! secretion and oligomer assembly, these 
structures are either degraded or directed into formation of less toxic fibril aggregates and 
plaques (Cohen et al., 2006; Morimoto, 2006). These are then affronted, limited and digested 
by microglia (Napoli et al., 2009). This concept is supported by findings, that accelerating 
fibrillization lowers oligomer load, correlating with reduced functional deficits (Cheng et al., 
2007). In support of this, plaque bearing mice with reduced oligomer levels showed an intact 
memory, unlike their littermates with normal levels of oligomers and memory deficits (Lesne 
et al., 2008). Interestingly, and somewhat unintuitive, A!- monomers have been reported 
neuroprotective (Giuffrida et al., 2010). 
 
1.3.3 Conclusion 
Integrating these findings, an “amyloid cascade theory” was formulated. Thereby, changes in 
A! metabolism lead to increased A!- protein quantities. This triggers a deleterious cascade: 
initial oligomer formation leads subsequently to synaptic dysfunction, resulting in 
inflammatory responses and plaque formation, followed by neuronal injury, dysfunction and 
death and consequent neurotransmitter deficits. These processes reinforce each other, and the 
cumulative effects are dementia and other cognitive clinical observations made in AD patients 
(Selkoe, 2002a).  A figure adapted from this publication (Fig. I04) illustrates the cascade: 
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Fig. I04: The "amyloid cascade" according to Selkoe et al.: Accordingly, increased A!- protein quantities result 
eventually in widespread neuronal and synaptic dysfunction. Furthermore, the processes portrayed reinforce each 
other in complex and only partially understood ways. 
 
2. From Risk Factors to Hypotheses  
In this section, in addition to the non-modifiable genetic risk factors described in chapter 1, 
several potentially plastic risk factors for dementia will be introduced. The question posed 
here is: Given no genetic disposition and a similar familial history of AD, why do some 
people develop the disease while others don’t? This review will focus on vascular alterations 
and hypoxia as possible pathogens (Khan et al., 2008) and develops the working hypothesis. 
 
2.1 Non-Vascular Risk Factors 
A wide range of risk factors has been reported for AD. For simplicity’s sake, non-vascular 
ones will only be listed. Higher risk for AD correlates with: high homocysteine concentrations 
in serum, smoking, alcoholism, high serum cholesterol, high intake of saturated fat, diabetes 
mellitus, head injury, menopause, migraine, lower education and depression (de la Torre, 
2004). Many of these are also risk factors for cerebrovascular diseases, a fact which indicates 
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that pathogenic mechanisms for AD and cerebrovascular diseases may be connected 
(Iadecola,  2004). 
 
2.2 Vascular Risk Factors 
The focus will now be put on vascular risk factors that have been found associated with AD. 
Again, findings will be listed without provision of a specific conceptual framework. 
One study investigated the type and number of brain pathologies that were present in patients 
with dementia. The question posed was, whether the underlying pattern of brain pathology 
influenced a patient's developing dementia or not. The compared groups had either a single 
brain pathology, such as AD, or presented a "mixed" picture, say AD and stroke. In the 
dementia group, over half of the patients presented a multiple, mixed diagnosis. For example 
the combination AD and infarctions combined was observed in 38% of dementia patients, 
while 30% had singularly "pure" AD. In those without dementia, 80% had no or only one 
diagnosis of associated brain pathology. Multiple diagnoses of brain pathologies show an 
odds ratio (OR) of 2.8 for dementia. This means that patients with various brain irregularities 
are nearly three times more likely to develop dementia (Schneider et al., 2007). This notion is 
supported by similar findings of faster dementia progression in AD patients with coexisting 
cerebral infarctions compared to individuals presenting only "pure" AD pathology (Sheng et 
al., 2007). Further support comes from the so called Nun-study, where small ischemic lesions, 
which by themselves would not alter cognition, aggravated dementia substantially in 
combination with AD (Snowdon, 2003). As shall be discussed later, the above mentioned line 
of evidence forms the basis for the working hypothesis of this study. 
Hypertension is associated with a higher risk for the development of AD. Evidence was found 
in the Systolic Hypertension in Europe (Syst- Eur) trial. Patients under antihypertensive 
treatment had a relative risk of 0.47 for dementia, compared to the non- treated group. 
(Patterson et al., 2008; Forette et al., 1998).    
In a mathematical approach performed by Goh et al., AD was found genetically associated 
with hypertension and myocardial infarction (Goh et al., 2007).  
Over two-dozen vascular risk factors (de la Torre, 2008) have thus far been related to AD by 
various epidemiological studies, amongst them being the Rotterdam study, the Kungsholmen 
project, the Framingham study, EURODEM, FINMONICA, the Honolulu- Asia study and the 
PROCAM project (Breteler et al., 2000; Aguero-Torres et al., 2006; Ruitenberg et al., 2005; 
Elias et al., 1993; Ivan et al., 2004). The recent EVA study showed that patients under 
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vascular care showed less progression of white matter disease, common in AD, compared to 
control subjects without treatment (Richard et al., 2010). 
Furthermore, twin studies have provided hints concerning the magnitude of non-genetic risk 
factors. Monozygotic twins have two times the incidence of AD compared to dizygotic twins 
(Raiha et al., 1996). Interestingly, the incidence ratio of the two groups for vascular dementia 
is one. Monozygotic twins show higher concordance rates than dizygotic ones, confirming the 
major role that genetic predisposition plays in AD development (Bergem et al., 1997). 
However, since genetic background is not sufficiently explicatory, the need to identify 
environmental components of AD pathogenesis remains of great importance. Another twin 
study comparing the relative importance of heredity and environment in AD development 
confirmed the major role of genetic predisposition, but found that vascular dementia was 
mainly caused by environmental factors, with heredity playing a minor role (Bergem et al., 
1997). This is interesting considering that AD and vascular dementia are sometimes described 
as opposite ends of the spectrum of one integrative disease mechanism (Roman et al., 2004). 
Further vascular risk factors are congestive heart failure, cardiac arrhythmia, thrombotic 
episodes, atrial fibrillation, atherosclerosis and hemodynamic abnormalities (de la Torre, 
2004). 
Summing this up, general findings such as ischemic and hypoxic tissue conditions are 
associated with a worse prognosis of dementia. They act both as cause and consequence in 
most of the above described pathologies. However, little is known about the direct influence 
of hypoxia on AD development and progression (Khan et al., 2008). 
 
3. Defining hypoxia 
The following chapter will introduce the basic concepts of oxygen sensing. 
 
3.1 Oxygen sensing and signalling 
The body has various specialized tissues through which it senses oxygen, for example glomus 
cells, the carotid body and neuroepithelial bodies in the lungs amongst others. Together they 
constitute a specialized homeostatic oxygen-sensing system, responding primarily to acute 
hypoxia, the physiologic range in oxygen tension ranging roughly from 40 to 100 mm Hg in 
the adult, while all tissues respond to severe hypoxia (Weir et al., 2005). At the molecular 
level, the hypoxia-inducible factor 1 (HIF-1) pathway is the key regulatory route by which 
gene expression is modified in order to facilitate adaptation and thus survival of cells under 
hypoxic conditions (Ke et al., 2006). Although other HIFs exist, we shall focus here on HIF-1. 
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It is an oxygen- sensitive transcriptional activator, inducing genes that participate e.g. in 
angiogenesis, iron metabolism, glucose metabolism and cell proliferation. HIF- 1 consists of 
two constitutively expressed subunits: a !- subunit and an oxygen- regulated "- subunit. Both 
need to associate as a heterodimer at a HIF- responsive element (HRE) at the target gene 
promoter to induce gene transcription. Through post- translational modification the "- subunit 
is degraded rapidly under normoxia. To be more specific, HIF prolyl- hydroxylases 
hydroxylate conserved proline residues of the "- subunit, allowing their ubiquitinylation and 
subsequent protein degradation by the proteasome. However, this occurs only under 
normoxia, since the hydroxylase is dependent on oxygen as a co- substrate. Under hypoxia it 
is inhibited, which stabilizes the "- subunit. It then interacts with other co- activators, most 
importantly HIF- 1!, and ultimately binds to the HRE. This gives way to gene transcription 
(Ke et al., 2006; Rey et al., 2010; Kaelin et al., 2008).  
This results in a variety of modifications. On a cellular level glucose metabolism is switched 
to oxygen- independent glycolysis (Dang et al., 1999). This results in a yield of only two 
adenosine triphosphate (ATP) per molecule glucose instead of 38 obtained through oxygen- 
dependent glycolysis. This switch occurs because under hypoxia oxydative phosphorylation 
does not occur. ATP- deprived cells elevate their ability to generate ATP through an increase 
in glucose uptake and an upregulation of enzymes such as Lactate dehydrogenase (Wenger, 
2002). Another reaction to low oxygen supply is induction of growth factors such as insulin- 
like growth factor 2 (IGF2), which downstream causes cell proliferation and survival 
(Semenza, 2003). On a bigger scale, hypoxic conditions also cause angiogenesis, because 
expression of the vascular endothelial growth factor (VEGF) is enhanced by HIF (Conway et 
al., 2001). 
 
3.2 Molecular findings linking HIF to AD 
Hypoxic conditions have been shown to upregulate BACE1 expression and activity, resulting 
in an increased A!- protein production, both in vitro and in vivo (Sun et al., 2006). 
Furthermore, HIF1 has been shown to bind the BACE1 promoter on a HRE, thus regulating 
gene expression (Zhang et al., 2007). Another study confirmed these findings, extending the 
hypoxia- mediated upregulation by another mechanism: the formation of reactive oxygen 
species (ROS) (Guglielmotto et al., 2009). Another component of the #- secretase complex, 
called APH-1A has been shown to be hypoxia- responsive too, again with a HRE in its gene’s 
promoter sequence, culminating in hypoxia- induced, increased A!- protein formation (Wang 
et al., 2006). In another study, using in vitro neural cultures, it has been shown that A!- 
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protein is able to activate the HIF1 transcription factor, which acts as a neuroprotective 
mechanism for the corresponding cells. It produces changes in glucose metabolism like an 
increased glucose flux, making the cells more resistant to the A!- protein toxicity (Soucek et 
al., 2003). This at first paradoxical finding supports the idea, that the effects of the A!- 
protein depend on its conformation, i.e. monomer, oligomer or fibril. However, because of 
this adaptation, or conditioning, the A!- resistant neuron population is more susceptible to 
glucose starvation, the latter being a feature of various vascular pathologies (Soucek et al., 
2003).   
 
4. Microglia and AD 
The first line of defence that the body has to react against the plaque depositions is a glial 
subpopulation called microglia, believed to play an important part in neurodegenerative 
conditions. This is why we focused on this population in our experiments. 
 
4.1 Origin, innate immunity, function, phenotype, activation  
Although microglia had been described before, Pio del Rio-Hortega, a student of Santiago 
Ramón y Cajal, is generally considered the „father of microglia“ for his pioneering work in 
the field. These cells constitute 10% of the central nervous system’s (CNS) cell population 
(Heneka et al., 2007), form part of the mononuclear phagocyte system (MPS) and represent a 
part of the innate immunity of the CNS (Ransohoff et al., 2009). Cells that are functionally 
equivalent to microglia can already be found in the invertebrate CNS, e.g. in leech (Hirudo 
medicinalis) (Morgese et al., 1983). Microglial cells occupy non-overlapping territories in the 
brain parenchyma, which they continually palpate and thus monitor through their numerous 
processes. In effect, the microenvironment around an individual cell is screened every couple 
of hours by this highly dynamic mechanism (Nimmerjahn et al., 2005). 
Where do microglia originate? At early stages of development (embryonic day 8 in mice), 
before the development of vasculature, myeloid cells can be found in the CNS with 
proliferative capacities (Alliot et al., 1999). However, their origin (i.e. linage) remains 
unclear. Postnatal, circulating cells of myeloid origin have been observed to enter the brain 
(Perry et al., 1985). It is not established, however, to what extend these cells persist to form 
part of the population of microglia observed in adulthood. Generally, microglia are believed 
to be a long-lived population of tissue macrophages, not unlike Kupffer cells in the liver 
(Ransohoff et al., 2009).  
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But what does long- lived mean? As will be discussed later, it is also of importance to know 
whether microglia age, in the sense that their correct and adequate function might be 
compromised. Dystrophic microglial cells accumulate in the aging human brain, suggesting 
that this cell population undergoes progressive deterioration. It is suggested that diminished 
replenishment and increased vulnerability contribute to the phenomenon (Streit, 2006). Since 
microglia are essential for the maintenance of normal brain function, deterioration of this cell 
population might be a crucial factor in the development of age- related neurodegenerative 
diseases such as AD.      
It needs further clarification whether the microglial population is morphologically uniform, 
since functionally it is highly heterogeneous (Gordon, 2003). This reflects the plasticity and 
versatility of this cell population in response to a wide array of signals. Microglia acquire 
different phenotypes according to stimuli, and their phenotype has to be seen as a point in a 
spectrum of possibilities, whose extremes pose the M1 and M2 activation profiles: Microbial 
compounds and pro-inflammatory cytokines cause the so- called M1 phenotype, marked by 
the production of pro-inflammatory cytokines and free radicals (Michelucci et al., 2009). The 
M2 phenotype, also called alternative activation, is less well defined, consisting of at least 
two subgroups separated through their expressional profile. However, it is thought to be anti-
inflammatory (Mosser, 2003). Interestingly, there is evidence that a phenotype switch takes 
place as Alzheimer’s disease related pathology progresses. In an animal model, microglia 
switch from an alternative, neuroprotective activation profile at the beginning of A!- 
pathology, to a classical M1- like, potentially neurotoxic phenotype at advanced stages of the 
disease (Jimenez et al., 2008). Furthermore, A!- fibrils and oligomers seem to stimulate 
microglia in different ways, leading to discrete secretory changes (Sondag et al., 2009). The 
receptors involved are scavenger receptors (including CD36), receptor for advanced glycation 
end products (RAGE), Toll- like receptor 2 (TLR2) amongst others (Lucin et al., 2009). This 
implies that the A!- protein can, dependent on the context, stimulate a variety of pathways 
and thus reactions. This in turn partially explains why, from a clinical point of view, in many 
neurodegenerative diseases it is not entirely clear whether inflammation and microglial 
activation are deleterious or beneficial (Lucin et al., 2009).  
 
4.2 Microglia and hypoxia 
Microglia play an important part in various clinical contexts and conditions, e.g. 
periventricular white matter damage (PVWD). It is one of the major causes of neurological 
impairment in premature newborns. Its aetiology, although being multi- factorial, is thought 
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to be linked to a state of hypoxia- ischemia through birth asphyxia (Kaur, et al., 2009), 
findings that have been confirmed in humans (Black et al., 2009). In this clinical context, 
microglia are appointed a critical role in PVWD. 
Accordingly, activation of microglia (i.e. inflammation) through hypoxic conditions could 
cause bystander injury to other CNS cells. In animal experiments, increased numbers of 
activated microglia have been observed to be present in the white matter of asphyxiated 
animal fetuses (Mallard et al., 2003).  
Glial activation is a consequence of hypoxia (Suk et al., 2004). The resulting oxygen 
deprivation has been found to induce shedding of nitric oxide (NO) and tumour necrosis 
factor (TNF-") in enriched microglial cultures, and cellular death after 12 hours exposition 
(Wang et al., 2007). How does this transform to the clinical context? Neither NO shedding 
after glial activation nor hypoxia cause wide neuronal damage by themselves. However, when 
combined, extensive neuronal death is the consequence (Mander et al., 2005). Microglia 
through inflammatory responses thus have the potential to cause neuronal damage. Hypoxic 
conditions seem to function as a possible trigger mechanism. 
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Materials & Methods 
 
1. Animals 
A murine model of Alzheimer’s disease (AD) was used, namely the Tg(APPswe, PSEN1dE). 
In humans, various mutations in key proteins are associated with familial AD. Animal models 
mime these in order to mimic the related pathology. More specifically, double transgenic 
mice were used. First, they express a chimeric mouse/human amyloid precursor protein 
(mo/huAPP) presenting the Swedish mutations (Haass et al., 1995) K595N/M596L, meaning 
that in the transgenic animal lysine at position 595 is changed for asparagine, and methionine 
for leucine at position 596, the location being before the A! sequence. The reason a chimeric 
protein is employed is because in mice no naturally occurring AD like disease has been 
observed, because apparently huAPP homologues in mice, APLP1 and 2, have different 
properties. Second, these animals present the mutation PSEN1dE9, meaning that exon 9 is 
deleted in the sequence of presenilin 1, a major constituent of the #-secretase complex. This 
mutation has been observed to selectively augment the APP cleavage product A!1-42 
(Jankowsky et al., 2004). A combinatory transgenic model, including both mutations for APP 
and PS1, has been described to show early amyloid deposition, thus being valuable as an 
animal model for AD (Borchelt et al., 1997; Savonenko et al., 2005). Both mutated proteins 
are under expression control of the prion protein promoter (Prnp) thus being limited to 
expression within the central nervous system (CNS). Visible amyloid deposits occur as early 
as 6 months, and various AD related pathologies have been described (Garcia-Alloza et al., 
2006; Yan et al., 2009). 
Animals were obtained from Jackson Laboratory (Strain name: B6.Cg-Tg(APPswe, 
PSEN1dE9)85Dbo/J, stock number 005864). 
 
2. Genotyping 
The material for DNA extraction was cut fingers from the process of numbering the animals. 
According to the manufacturer’s instructions, the DirectPCR DNA Extraction System 
(Viagen) was employed, with the modification of added proteinase K (Roche). Amplification 
was carried out using Dominion MBL-taq polymerase. Primers were designed to match the 
APP coding sequence (forward 5'- CTT GTA AGT TGG ATT CTC ATA TCC G- 3', reverse 
5'- GAC TGA CCA CTC GAC CAG GTT CTG- 3'). The electrophoresis was carried out 
according to standard procedures.  
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3. Hypoxia treatments 
Two groups of animals were compared - those under hypoxic exposure and those under 
normoxia, corresponding to 8% and 21% oxygen respectively, for 20 consecutive days. Both 
groups were kept in their particular setting in a specially constructed oxygen-variable 
chamber (Coy Laboratory Products). No preconditioning of the hypoxia group was 
undertaken. Atmospheric conditions were kept stable and automatically monitored for 
changes (gas guard, Thermo Electron Corp.), in which case the system re-established the 
experimental conditions (oxygen controller, Coy Laboratory Products). Furthermore, the 
oxygen concentration was checked manually every second day (combustion test kit, 
Bacharach), whereby a difference of 0.5% from the above-mentioned value was still 
considered acceptable. Humidity inside the chamber was always kept below 80% using 
absorbing silicon, as otherwise the animals would have died. CO2 was filtered through a 
special pump system employing sodium, as part of the specially designed chamber. All parts 
of the system and reagents were replaced according to their functional state. Access to the 
chamber for feeding and cleaning occurred through an air lock leaving the conditions in the 
chamber unaffected. Light, feeding and cleaning cycles were kept uniform for all groups. All 
treatments were in accordance with ethical standards of the University of Sevilla (Spain) and 
approved by the Committee of Animal Use for Research of the Malaga University (Spain) 
according to the European Union Regulations.  
 
4. Tissue preparation/ HCT measurement 
In order to confirm the exposure to hypoxia or normoxia, the hematocrit (HCT) of all animals 
was measured.  
Animals were taken from the chamber and immediately sacrificed by injection with 
Thiobarbital (Braun, 0.15 mL, if this did not suffice, further injections were administered). No 
reflexes to pain, both in tail and eye, were taken as indicator of death. Animals were then 
fixed to a board with needles and blood was drawn for HCT measurements. The following 
surgical procedure was undertaken to get access to blood from the right coronary auriculum 
for analysis: After desinfection with 70% ethanol, skin was cut open epigastric to 
suprasternal, then moved aside through subcutaneous incisions. Subsequently an infracostal 
horizontal incisition opened the abdominal cave. It was important to cut in on the right-hand 
side of the animal as this assured no damage to the heart or associated structures. From here, 
the diaphragma was dissected, opening the thoracic cave. Then, the ventral costal cage was 
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removed, exposing the heart. An incisition in the right auriculum was made, while hearts were 
still beating, and released venous blood was collected in a capillary. It was then sealed with 
plasticine and centrifuged for 5 min at 5000 rpm. To calculate HCT, the length of the 
capillary part with solid matter was divided by full capillary length (parts sealed with 
plasticine were excluded from calculation).  
After blood withdrawal, animals were decapitated by guillotine. Skin was then removed from 
the skull with a median incision. Using pliers the skull was opened at point Bregma. With the 
same tool the skull was carefully removed around the brain. This was then put into a Petri 
dish filled with PBS at 4°C. Brains were sliced in half, with the left hemisphere being put into 
liquid nitrogen and later stored at -80 °C for protein analysis experiments, while the right was 
put in PFA 4% at 4°C. Total surgery and storage was exercised within 10 minutes after the 
declared death of the animal. 
For paraffin fixation the tissue was placed 12 h in PFA 4% and stored at 4°C. Then, samples 
were transferred to ethanol 70% until paraffin inclusion 9h later. Half brains were fixed using 
a uniform protocol automatically carried out by an Inclusion automat (ASP300S, Leica). 
Paraffin blocks were stored at 4°C until further processing. Slicing was done on a microtome 
(RM2125RT, Leica) at 20 µm. 
 
5. Immunohistochemistry 
All sections were deparaffinized with help of xylene and a row of decreasingly concentrated 
ethanol and finally water (2x 100% 5’, 90% 5’, 80% 5’, 70% 5’, 3x distilled water total 5’).  
 
5.1 A!1-42 staining 
Two different methods were used for plaque staining. An antibody based approach was 
employed considering various optimization techniques (Cummings et al., 2001). A second 
approach included the reagent Thioflavine-S, described below. First, peroxidase remaining 
activity was terminated by incubation with H2O2 at 3% for 15 minutes, followed by a wash 
step (3 times 5 minutes in distilled H2O). Then antigen retrieval was performed in a bath of 
99% formic acid for 3 minutes, followed by another wash step. Subsequently, slices were 
blocked in IHC blocking solution (PBS with 5% skim milk) for 1 hour at room temperature. 
Afterwards, the primary antibody in blocking solution was added and left to incubate at 4°C 
over night (rabbit polyclonal A!1-42, Calbiochem, 1:100). Following a wash step with 0.1% 
Triton reagent (Sigma) added PBS (from hereon referred to as PBTriton), the secondary 
antibody solution (IgG goat anti-rabbit, Dako) in blocking solution was put and left for one 
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hour at room temperature in a wet chamber. After another wash with PBTriton, revelation 
procedure was carried out as described in the manufacturer’s instructions of the EnVision + 
System-HRP kit (Dako) using the DAB chromogen. After 2 minutes exposure the chromogen 
was inactivated with an additional wash. Sections were mounted with aqueous mounting 
medium (Dako), left to dry and sealed with colourless nail polish (Barbie Manicure Set).  
 
5.2 Iba1 staining 
Iba1 is an EF-hand calcium-binding protein specifically expressed in macrophages and 
microglia, that was employed as a target to evaluate the microglial population. After 
deparaffinization of tissue sections, intrinsic peroxidase activity was inactivated by incubation 
in 3% H2O2 for 30 minutes and a subsequent wash step (distilled water 3x 5’). Antigen 
retrieval was performed by incubation with 10 mM citric acid (pH 6) at 95°C for 20 minutes 
followed by 45 minutes at 4°C. After another wash step, unspecific antigens were blocked 
with a solution of skim milk (5%) in PBS for 1h. Then, the primary antibody (Iba1, 
polyclonal rabbit, Wako) in skim milk solution (1:500) was applied for 1h at room 
temperature. Following a wash step with PBTriton, a revelation kit was used to stain the 
marked areas (EnVision+System-HRP/DAB, anti-rabbit, Dako) with 1h incubation with the 
secondary antibody and 4 min DAB exposure (Fig. MM01). Sections were mounted and 
sealed as described above.  
 
 
Fig. MM01: Iba1 stained microglia surrounding what appears to be a plaque. Scale is 50 µm. 
 
6. Other staining techniques 
 
6.1        Thioflavin- S staining 
The fluorescent reagent Thioflavin-S (Sigma) reacts with !-sheet structures, and thus 
recognizes A!-plaques as well as neuro-fibrillary tangles (NFT). Vessels were observed to 
show high autofluorescence under this type of staining due to unknown properties, which 
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limited its use for quantitative purposes. It was however effective for double staining 
procedures (Fig. MM02).  
 
 
 
Fig. MM02: triple- staining with Iba1(microglia), Thioflavin-S (plaques), DAPI (nuclei): Microglia surrounding 
plaques and limiting their expansion 
 
Pre-stained slices were washed and then incubated with 0.05% Thioflavin-S in 50% ethanol 
for 8 minutes in darkness. This solution was then filtered (filterunit SteriCup, Millipore). 
Afterwards the sections were treated 3 times 10 seconds with 80% ethanol to remove auto-
fluorescent background noise, followed by a similar wash step with distilled water. 
Fluorescence Mounting Medium (Dako) was used for mounting. The signal was finally 
obtained under UV-light (Fig. MM03).  
 
 
Fig. MM03: Plaques in the hippocampal formation, Thioflavin-S stained 
 
 
6.2 Prussian staining 
This technique was used to stain ferric iron, as can be found in hemorrhage. This method was 
used to assess whether there was excessive extra-vascular bleeding under the treatment 
conditions. After deparaffinization and rehydration, sections were stained for 20 min in a 
solution made up in equal parts of a: 20% aqueous solution of hydrochloric acid and b: 10% 
aqueous solution of potassium ferrocyanide (protocol from IHCworld). Counterstaining was 
done with nuclear fast red (Sigma) for 5 min.   
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6.3 Hematoxylin and Eosin staining 
In order to evaluate structural changes under treatment, especially angiogenesis, Hematoxylin 
and Eosin (HE) staining was employed. According to standard protocols, Accustain Harris’ 
hematoxylin and eosin solutions (Sigma) were used. 
 
7. Cell Culture 
To obtain primary microglia populations, a procedure was employed that enriched these cells 
in the cell culture (Saura et al., 2003). The cultures obtained are mixed. But due to the lack of 
an established microglial cell line and our aim, to monitor the cells’ response as close to their 
natural state as possible – for which the interaction with other cell types is also important – 
the usage of this method was decided on. It needs to be pointed out that the data obtained 
from such a culture, concerning their relevance for microglial properties, is restricted and still 
a matter of debate (Saura, 2007). Thus, one might want to call this culture type more exactly 
microglia- enriched cultures (Jimenez et al., 2008), as will be done from hereon.     
Microglia- enriched primary cultures were prepared from newborn C57BL/6 mice (1–3 d, 
Jackson Laboratory). Animals were decapitated, and the cerebrum (telencephalon) removed. 
Then, while conserved in sterile PBS at 4°C, the meninges were removed under a microscope. 
For each cell seeding cycle this procedure was performed for all brains at a time to keep 
uniformity. Briefly, the dissected brains were treated for 5 min with DMEM-medium (Gibco) 
(with trypsin 0.25% + EDTA 1mM (Gibco)) at 37°C. During these 5 minutes incubation, the 
cells were mechanically dissociated three times using a pipette for gentle aspiration. The 
trypsin was stopped using complete DMEM/F12 (50:50, Gibco; added 10% FBS (Hyclone)). 
Subsequently, the debris was eliminated by filtration (cell strainer, 40 µm, BD Falcon) and 
the cells were seeded (250.000 cells/mL) in complete medium DMEM/F12, 10% FBS added 
L-glutamine (Gibco), nonessential amino acids (PAA), 1% gentamycin (Sigma) and 
penicillin-streptomycine (Sigma) on 12-well-plates (Nunc) pretreated with poly-D-lysine 
(Sigma). The cells were cultured at 37°C in humidified 5% CO2/ 95% atmosphere, with 
medium being replaced every three days. Once a well had reached about 90% confluency, a 
mild trypsinization step was performed: 0.25% trypsin + EDTA 1mM was diluted 1:4 in raw 
DMEM medium (Gibco). It has been estimated that under these conditions the calcium 
concentration is higher than the sequestering capacity of the present EDTA. The non-
sequestered free calcium partially inhibits trypsin (Saura et al., 2003). This results in the 
observed partial trypsinization. The culture was left for 20 min with the solution at 37°C. 
After a washing step with sterile PBS at 37°C, new complete medium was added, and cells 
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left to expand. In the protocol used, a yield of up to 98% microglia was reported (Jimenez et 
al., 2008), however, it was only possible to generate a mixed culture with 50% of the 
population being microglia (Fig. M04). 
 
 
Fig. MM04: Primary, microglia- enriched cell cultures; directly after isolation (top two images) and after 
enrichment procedure (bottom two images) 
 
 
8. Immunocytochemistry 
For the identification of microglia the Iba1 antibody was used (see above, 
Immunohistochemistry). A small glass plate of 0.5 x 0.5 cm was prepared to be left in a well 
and overgrown by cells. Prior to that the glass was made sterile and incubated with poly-L-
lysine for 2 h so that cells could attach. First, the well was cautiously washed with PBS. Then 
the platelet was incubated for 1 h with PFA at 4% at room temperature. After a wash step 
with PBS, antigen-block was done with skim milk solution, as described above. Subsequent 
incubation with the primary antibody in milk solution (Iba1, 1:500) was for 2 h. The 
fluorescent secondary antibody (AlexaFluor 568, 1:500 in milk solution, anti-rabbit, 
Molecular Probes) was left to bind for 1 h in darkness. Counterstaining of nuclei was done 
with DAPI (1:1000 in PBS, Sigma) (Fig. MM02 and MM04). For mounting, a special 
medium (Fluorescent Mounting Medium, Dako) was used.  
 
 
 20 
9. Hypoxia treatment of cells/ XTT assay  
Prior to treatment the cells were plated in a 96-well-plate (Nunc) at 8.000 cells per well and 
left one day to settle. Two groups were formed: cells under hypoxia (0.5% O2, 5% CO2) and 
those under normoxia (atmospheric conditions). The hypoxic exposition was possible through 
the use of an incubator with variable oxygen concentration (hypoxic chamber INVIVO2 300, 
Ruskinn Technology) and controlled and adjusted with gas mixer q (Ruskin). Exposition 
times were 4, 24 and 48 hours respectively. The XTT assay (Roche) is based on the principle 
that live cells reduce tetrazolium salts into coloured formazan compounds (Scudiero et al., 
1988), which can then be quantified through measurement of optical density (O.D.). It is 
commonly used as a procedure to measure proliferation and is thus an appropriate solution to 
quantify cells and assess their viability. The assay was carried out according to the 
manufacturer’s instructions. O.D. was measured using a Multiscan Spectrum luminometer/ 
spectrophotometer (Thermo Electron Corp.), right after addition to wells and then at the 
corresponding point in time. For analysis, measurements were corrected with this starting 
value (valueX – value0). Experiments were repeated three times with eight wells for each time 
point and repetition. All measurements were later collected according to group, and the mean 
normalized to the mean value at 4 h normoxia.  
 
10. Protein extraction and quantification 
For protein extraction, first the wet mass of hemibrains was determined. They were then 
homogenized manually employing a Dounce grinder (Sigma) with 4x mass of PBS added 
including protease inhibitor cocktail (1:1000, Sigma) and phospatase inhibitor (1:100, Sigma). 
An aliquot was centrifuged 10 minutes at 2000g at 4°C and supernatant was stored at -20°C 
and subsequently used for WB experiments. For ELISA sample preparation, 8.2M guanidine 
HCl/ 50mM Tris HCl solution was added to a final molarity of 5M. The prepared sample was 
incubated 4h at room temperature with casual mixing. After incubation, the sample was stored 
at -20°C until further use. 
Sample concentrations were determined by the method of Lowry, using the kit DC Protein 
Assay (Biorad) following manufacturer’s instructions. BSA was used as protein for the 
standard curve. A correlation coefficient of R%>0.997 was considered acceptable.  
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11. Western blot (WB) 
For polyacrylamide gel electrophoresis (PAGE) the Mini-protean system (BIORAD) was 
used. Electrophoresis was performed with electrophoresis buffers at 150 mV (Tab. MM01). 
In the case of WB detection of A! protein, Tricine- SDS-PAGE had to be employed. This is 
because the target protein, due to its small size of 4.7 kDa, does not enter the gel with the 
electrophoresis protocol used for standard SDS-PAGE. Following instructions of Schägger, 
the protocol was modified (Schägger, 2006). 
Acrylamide gels are characterized by two values: For one "x % T", which equals the total 
percentage concentration of acrylamide and the crosslinker bisacrylamide combined. The 
second value, "x % C" corresponds to the percentage concentration of the crosslinker relative 
to the total concentration. A gel of 16% T, 6% C and 6M urea was used. This led to a gel 
resolution of 1- 70 kDa. The high crosslinker concentration together with the added urea 
increases the resolution, especially of small proteins, further.  
Furthermore, no SDS was added, as this would have denaturalized A! protein oligomers and 
fibrils. Our intention was to visualize the quantities of oligomers of different sizes. 
 
  Anode buffer (10x) Cathode buffer (10x) Gel buffer (3x) 
Tris (M) 1.0 1.0 3.0 
Tricine (M) - 1.0 - 
HCl (M) 0.255 - 1.0 
pH 8.9 ~ 8.25 8.45 
 
Tab. MM01: Buffers according to the Tricine- (SDS)-PAGE protocol described by Schägger. 
 
Gels were subsequently transferred to PVDF membranes, which prior to use were activated 
with methanol. Employing a semi-dry transfer system (SIGMA) gels were transferred for 2 h 
using transfer solution (Tris 25 mM, glycine 192 mM and 20% methanol). Current in mA was 
calculated by membrane area in cm" times 1.2 as a fixed value. 
Afterwards, the membranes were blocked for 1 h in blocking solution. Then the primary 
antibody in blocking solution was incubated overnight in a wet chamber (mouse monoclonal 
6E10 from COVANCE 1:500) Then, membranes were washed 4 times in PBS supplemented 
with 0.1% Tween-20 (PBTween-20) for 5 min each turn, following incubation with the 
peroxidase-conjugated secondary antibody in blocking solution for 1 h at room temperature. 
After another washing step, signal detection was done using ECL PLUS Western Blot 
Detection System kit (GE HEALTHCARE). 
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12. Dot blot 
For dot blots, 5 µg protein in 2 µL sample were applied directly onto a dry nitrocellulose 
membrane (Hybond) and left to air dry. Then the membrane was transferred to blocking 
solution for 1 h. Incubation with the primary antibody (A11, Invitrogen, 1:500) in blocking 
solution was over night at 4°C. Incubation with the secondary antibody, revelation and blot 
analysis was done as described for WB.     
Signals from blots were visualized using a Typhoon Scanner (9400 variable mode imager, 
Amersham Biosciences), and subsequent image analysis and signal quantification was done 
with ImageQuant (Amersham Biosciences). 
 
13. ELISA 
This immunoassay was employed to detect levels of human A!1-42. The principal is based on 
the quantitative detection of the target protein by its binding to specific antibodies, one coated 
onto a plate and one in solvent, the latter being detected by means of a horseradish 
peroxidase-labelled secondary antibody through substrate conversion. The intensity of the 
coloured product is directly proportional to the concentration of human A!1-42 in the original 
specimen.  
Thawed ELISA samples in guanidine 5M were diluted 1:50 in reaction buffer (BSAT-DPBS). 
This dilution factor was determined prior to experiments. It was taken into account that the 
final solution content of guanidine should not exceed 0.1 M since standard curve alterations 
were observed above (see manufacturer’s instructions, ELISA kit, Invitrogen). After a 
subsequent centrifugation step at 16,000 g for 20 minutes at 4°C, the supernatant was 
carefully decanted and stored on ice until used for the assay. 
For standard curve samples, lyophilized synthetic peptide was used (provided in kit). The 
protein powder was reconstituted (see corresponding buffer) to a concentration of 1 µg/mL, 
aliquoted and stored at -80°C until further use. For generation of the standard curve, buffer 
components and dilutions had to be the same as in samples of unknown A!1-42 content. 
Since the test’s upper detection limit is located at 1000 pg/mL, the required dilution factor for 
samples was determined to be 1:100 in sample diluent buffer (provided in kit). The buffer 
used to generate the standard curve was adjusted accordingly. Serial dilutions yielded the 
linear standard curve through linear regression analysis and a correlation coefficient R%>0.995 
was considered acceptable. To all samples, both of known and unknown A!1-42 content, 
protease inhibitor was added (1:1000). 
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In the actual procedure, standards, controls and samples were added to 8 well strips of a 96 
well plate and incubated with the primary antibody 3 h at room temperature under constant 
shaking on a shaking block. After repetitive washing with the provided solution, the 
secondary antibody was incubated at room temperature for 30 minutes. After another washing 
step, the provided chromogen was added, and stopped after 10 minutes with the provided stop 
solution to not exceed an optical density (O.D.) of 2.0 to ensure linear measurements. O.D. 
was taken at 450 nm using the luminometer described above.     
 
14. Plaque load estimation/ Stereology/ Microglia count 
Hippocampal A!- protein 1-42 immunostaining from 8- and 14- month- old APP/PS1 mice 
was observed under an Olympus BX61 microscope using a 10x objective. Stereologic tools 
were from the Olympus CAST software package. Images were acquired with an Olympus 
DP70 high-resolution digital camera. The camera settings (white balance, light intensity etc.) 
were adjusted at the start of the experiments and throughout maintained for uniformity. 
Digital images (five sections per mouse) were analyzed using ImageJ software (NIH 
freeware).  
The dentate gyrus was chosen as sample area for plaque load determination. Neuroanatomy 
was assessed using a Mouse Brain Atlas (Paxinos). In each animal, the first section where this 
structure reaches the ventral side of the brain was identified and taken as starting point. From 
here two sections, respectively caudal and ventral, were also taken into consideration.  
The sample area (the dentate gyrus) was then manually outlined and the total area assessed 
using CAST software. A digital image was then taken off each section, with a constant 0.625 
pixels per µm2. The image was then edited using ImageJ: After colour conversion to black-
and-white (8-bit), the plaque area within the dentate gyrus was identified by bright-level 
threshold, the level of which was maintained for uniformity throughout the experiment. The 
gray-scale image was thus converted to a binary image, with only plaque areas remaining 
within the sampled dentate gyrus area. This image was compared to the original, and through 
the automatic selection process erroneously selected items were manually removed, such as 
unspecific or intracellular staining. Using the “Analyze Particles” option, and maintaining the 
same settings for uniformity, the plaque areas were analyzed for area, number and perimeter 
(to evaluate the reactive surface).   
Plaque load was defined as percentage of total dentate gyrus area stained for A!1-42. It was 
calculated and defined by (sum plaque area/ sum dentate gyrus area) x 100. The sums were 
taken over all slides and a singular value for plaque load (percentage) was calculated for each 
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animal. The number of plaques was normalized to sampled area (n/mm2). Size distribution 
was not evaluated. The perimeter was also normalized to sampled area.  
To evaluate the number of microglia a different approach was taken, namely the optical 
dissector method, in which each section is analyzed in a systematically random manner. At 4x 
magnification, the dentate gyrus was selected as described above (5 sections per animal). But 
since not the total area was taken for sampling, points were thrown randomly but 
systematically over the selected area using CAST software (x and y parameters 4, 4, 4, 4), 
with each point being appointed a constant area of 13,926.4 µm2. All points in the area were 
counted and then used to calculate the sample area.  
Microglial cells were counted at 40x magnification. The counting frame was 80%, giving a 
dissector area of 28,521.3 µm2. Meander sampling or the percentage of total area being 
sampled was 50% of dentate gyrus. The dissector height was 20 µm, and 15 µm corrected. 
Using the formula below, the total number of cells in the dentate gyrus was calculated. Cells 
that did not stain to satisfaction or were recognized as not being integer were not taken into 
consideration, and the typical morphology of microglia was a criterion as well. 
 
(1) cT = (cC x a x p)/ d  
(2) a = (A(p) x zT)/ (A(d) x zd) 
 
cT.. total cell count 
cC.. cells counted in sample area 
a.. constant 
p.. number of points in sample area 
d.. number of dissectors 
A(p).. area assigned to point 
A(d).. area assigned to dissector  
zT.. dissector height (section thickness after cutting) 
zd.. real dissector height (after immuno-staining treatment) 
 
The calculated value cT gives an approximation of the size of the microglial population in the 
dentate gyrus.   
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In order to count microglia normalized to plaque area ("plaque occupancy", which will be 
defined in the results chapter under 7.), in hypoxia and in normoxia, plaques in a sample area 
were selected in a systematically randomized manner, and microglia around them counted as 
in the example described above (Fig. MM05A). The plaque size was also analysed as 
described above (Fig. MM05B- D). These two values obtained were then pooled for each 
group and analyzed, normalizing the number of microglia to plaque size.  
 
 
Fig. MM05: Assessment of the number of microglia around A!- plaques. (A) Groups of microglia in the sample 
space are selected randomly. The number of microglia around a plaque (B) is determined (green/ red dots). 
Using ImageJ software plaques are analyzed in number and size, by first creating a black mask (C) and then 
analysing the plaques employing it (D) in number and size. 
 
 
15. Statistics 
Data were expressed as mean ± SD. Comparison between two groups was carried out by t-test 
(two-tailed), comparison between several groups was done using one-way ANOVA followed 
by Tukey’s post hoc multiple comparisons test. The confidence interval was set to be 95%. 
Analysis software SPSS and SigmaStat were employed.  
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16. List of materials 
 
Chemicals Ref. No. Company 
   
Acrylamide (40%)/ Bis solution 29:1 (3.3%C) 1610146 BIORAD 
APS  AMERSHAM BIOSCIENCES 
Beta Amyloid peptide SP-BA42-1 INNOVAGEN 
BSA A8022 SIGMA 
DMSO D2650 SIGMA 
F12:DMEM 50:50, sterile 21331 GIBCO, INVITROGEN 
FBS SH30070.03 HYCLONE 
Gentamycine solution 10 mg/mL G1272 SIGMA 
Glycerol  SIGMA 
Guanidine hydrochloride (CH5N3.CIH) G4505 SIGMA 
HCl (37% conc.)  SIGMA 
HFLP 105228 SIGMA 
L-glutamine M11-004 GIBCO, INVITROGEN 
Lipopolysaccharides (LPS) from E. coli 026:B6 L2654  SIGMA 
Methanol  SIGMA 
Non-essential aminoacids M11-003 PAA 
Parafin 6060 11609 
INSTRUMENTACIÓN 
TÉCNICO ANALÍTICA S.L.  
PBS, sterile  10010 GIBCO, INVITROGEN 
Penicilline/ streptomycine solutions INVITROGEN 
PFA  SIGMA 
Poly-D-lysine hydrobromide P6407 SIGMA 
TEMED  35925 SERVA 
Thiobarbital (sodium thiopental) BRAUN 
Tricine  SIGMA 
Tris Base  SERVA 
Trizol reagent 15596-026 INVITROGEN 
trypsine 0.25%+EDTA 25200-056 GIBCO, INVITROGEN 
TWEEN 20 P9416 SIGMA 
Urea  SERVA 
   
HE stain   
Accustain Harris hematoxylin solution HHS32 SIGMA 
Accustain eosin and solution HT110216 SIGMA 
Nuclear Fast Red Counterstain   
Aluminium sulfate (Al2(SO4)3xH2O) 5% in H2Od 368458 SIGMA 
Nuclear fast red 0.1% in above solution, boil to dissolve, 
filter 60700 SIGMA 
Other stains and reactives   
DAPI  SIGMA 
Thioflavine- S  SIGMA 
Triton X-100 solution 93443 SIGMA 
Ethanol  SIGMA 
Hydrogen peroxide 30% 95313 SIGMA 
Prussian stain   
HCl 37% conc. 1:5 in H2Od  SIGMA 
Potassium ferrocyanide, Trihydrate (K4Fe(CN)6.3H2O), 
10% in H2Od P-3289 SIGMA 
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Mix above 50:50   
Silver stain   
Processor Plus portioning device GE HEALTHCARE 
Silver staining kit, Protein, "Plus One" 17115001 GE HEALTHCARE 
   
Antibodies   
   
A11 (1:1000, polyclonal, rabbit anti- mouse) AHB0052 INVITROGEN 
A!1-42 (1:100, polyclonal, rabbit anti- mouse) 171609 CALBIOCHEM 
A! 6e10 (1:1000, monoclonal, anti- mouse, IgG) SIG39399 SIGNET, COVANCE 
Alexa Fluor 568 (1:500, red, goat anti-rabbit) A11036 MOLECULAR PROBES 
Alexa Fluor 488 (1:500, green, donkey anti-mouse) A11055 MOLECULAR PROBES 
GFAP (1:200, monoclonal, anti- mouse, IgG) 3670 CELL SIGNALLING 
Iba1 (1:500, polyclonal, rabbit anti- mouse) 1919741 WAKO 
   
Primer   
   
APP   
5'- CTT GTA AGT TGG ATT CTC ATA TCC G- 3' 
(forward) specific INVITROGEN 
5'- GAC TGA CCA CTC GAC CAG GTT CTG- 3' 
(reverse) specific INVITROGEN 
stored at -20°C   
   
Devices/ Tools   
   
Detection system Western Blot RPN2132 GE HEALTHCARE 
Electrophoresis power supply EPS 601 GE HEALTHCARE 
Image Quant  AMERSHAM BIOSCIENCES 
Mini Protean system   BIORAD 
Multiscan Spectrum luminometer/ spectrophotometer THERMO ELECTRON CORP. 
Nanodrop 2000  THERMO SCIENTIFIC 
Noria rotator  SELECTA 
Power- Pac 300 electrophoresis power supply BIORAD 
Thermomixer comfort  EPPENDORF 
Transfer platform WB  SIGMA 
Typhoon 9400 variable mode imager AMERSHAM BIOSCIENCES 
Typhoon Blue Laser Module  AMERSHAM BIOSCIENCES 
CAST System   
Mounted PRIOR platform PROSCAN II PRIOR 
Olympus BX61  OLYMPUS 
Olympus DP70 camera  OLYMPUS 
Software package  OLYMPUS 
Cell culture related   
Cell strainer 40 µm 352340 BD FALCON 
Gas mixer "q"  RUSKINN TECHNOLOGY 
Hypoxic chamber INVIVO2 300 RUSKINN TECHNOLOGY 
Incubator Series II Water Jacketed CO2 Incubator 
THERMO FISHER 
SCIENTIFIC 
Microscope CKX41  OLYMPUS 
Microwave   LG 
Waterbath  SELECTA 
Working platform TWO30  FASTER 
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Working platform BIO48  FASTER 
Centrifuges   
Centrifuge 5415R   EPPENDORF 
Centrifuge 5415D  EPPENDORF 
Centrifuge 5810R   EPPENDORF 
Centrifuge GS-15R  BECKMAN 
SPEEDVAC GYROVAP L  HOWE 
Hypoxia- related   
Combustion test kit   BACHARACH 
Gas guard   THERMO ELECTRON CORP. 
Hypoxic chamber  
COY LABORATORY 
PRODUCTS 
Oxygen controller  
COY LABORATORY 
PRODUCTS 
Slicing   
Inclusion automat (parafin) ASP300S LEICA 
Microtome RM2125RT  LEICA 
Surgery related   
HCT centrifuge "Centrolit II"  SELECTA 
KL1500 LCD light  OLYMPUS 
Microscope SZX16  OLYMPUS 
   
Consumer articles   
   
Amersham Hybond-P PVDF transfer membrane RPN303F GE HEALTHCARE 
Culture plates, plastic, various NUNC 
THERMO FISHER 
SCIENTIFIC 
Filter unit "Stericup"   MILLIPORE 
Gloves  NATURFLEX 
Hybond Blotting Paper RPN6101M AMERSHAM BIOSCIENCES 
Hybond-ECL nitrocellulose membrane RPN2020D AMERSHAM BIOSCIENCES 
Low profile microtome blades LEICA 819 LEICA 
Micro tube 1.5 mL 72690 SARSTEDT 
Mounting slides "REAL capillary gap microscope slides" S2024 DAKO 
MultiGuard barrier tips (with filter)  35230 SORENSON, BIOSCIENCE 
Pipettes "pipetman"  GILSON 
Pipettes, glass   GILSON 
Pipettes  EPPENDORF 
Pipettes, sterile, serologic, plastic  BD FALCON 
RNAse free PCR micro tubes 0.2-1.5 mL AXYGEN 
Syringe micro-fine U-100 insulin 0.3 mL 320838 BD 
Surgey instruments  SURGICAL123 
15/50 mL PP- Test tubes, sterile 227261 GREINER BIO-ONE 
   
Kits   
   
AEC+Substrate K3469 DAKO 
DAKO EnVision+System-HRP (DAB) for mouse primary 
antibodies K4007 DAKO 
DAKO EnVision+System-HRP (DAB) for rabbit primary 
antibodies K4011 DAKO 
DAKO Faramount Aqueous Mounting Medium S3025 DAKO 
DAKO Fluorescent Mounting Medium S3023 DAKO 
ELISA human beta- amyloid 1-42 kit KHB3441 INVITROGEN 
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RC-DC protein quantification kit (method after Lowry) BIORAD 
XTT kit   ROCHE 
   
Software   
   
CAST software package  OLYMPUS 
Image J  NIH 
Oligo 6  
MOLECULAR BIOLOGY 
INSIGHTS 
Origin 7.0  ORIGINLAB CORPORATION 
SPSS  IBM 
SigmaStat  STATCON 
   
Animals   
   
Tg(APPswe, PSEN1dE) mice  JACKSON LABORATORY 
   
Other solutions   
   
supplement   
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Results 
 
1. Working hypothesis 
Clinical findings have linked multiple pathologies to AD, as has been described in the 
introduction. Coexistence worsenes dementia, the clinical hallmark of the disease, as 
compared to pure AD. One general common denominator of these associated pathologies, 
such as stroke, is the presence of hypoxic tissue condtions. The question was asked, whether 
there exists a mutual, causal interaction between hypoxia and AD pathology, that could 
explain the clinical observations. Alternatively, the worsened clinical state of multiple brain 
pathologies could "simply" be the consequence of multimorbidity, i.e. accumulated disease 
load, without any causal interaction between the constituents.  
 
2. Physiologic response under the influence of hypoxia 
First it was examined whether the transgenic (tg) animals responded to hypoxia in the same 
way that control (c), i.e. wild- type (wt) littermates do. To our knowledge, this has not been 
evaluated before. 
Animals at the ages of 8 and 14 months (mo) were subjected to hypoxic treatment with 8% 
oxygen (hypoxia, Hx) or 21% normoxia (Nx) for 20 days. Sample size was 3 for the 8 month 
age group and 4 for the 14 month group, each for Hx and Nx as well as transgenic and control 
littermates, respectively, giving a total of 28 animals. The animal age corresponds to juvenile 
and old age, as the mean age of mice is around two years. The plaque desposition onset of the 
transgenic animal model lies at about 6 months, so by choosing 8 and 14 month old animals, 
it was possible to evaluate amyloid deposition at an early stage, as well as in a progressed 
state. Treatment of older animals or longer periods of hypoxia resulted in a high mortality 
(data not shown). All animals were fed and exposed to the same constant light and dark 
cycles.  
Behavioural observations were difficult to standarize, as the hypoxic treatment occured in a 
sealed chamber. Testing would have included stopping the exposure temporarilly. As this was 
not deemed acceptable under the working hypothesis, behavioural testing was not performed. 
However, as assessed by mere observation, animals under hypoxia tended to move very little, 
as the treatment posed a significant challenge to their fitness. They were not observed to be 
more aggressive or otherwise presenting altered behaviour, compared to the control 
littermates under normoxia.  
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Neuronal damage was not assessed, as our primary marker of causal interaction between 
hypoxia and AD was A!- protein deposition. It is likely, that neuronal damage is more 
prominent in animals subject to hypoxia, both within the transgenic and the control group. 
However, this was not a focus of the experiments. 
Two markers were chosen to evaluate the adaption to the hypoxic stimulus: First, hematocrit 
(HCT), which is defined as the percental volume of cellular elements in the blood. In 
principle, hypoxia stimulates erythropoesis, increasing oxygen transport capacities of the 
blood through increased cell number and percentage. Second, weight loss was recorded as 
difference between weight at the beginning and the end of the treatment.  
Comparing HCT within the age groups per treatment, there was no significant difference 
observed between transgenic animals and control littermates (Tab. 1, p> 0.05, One Way 
ANOVA/ Tukey for all groups, p> 0.05, Student's T- test for age/ treatment group, e.g. 8 mo/ 
Hx/ tg vs. 8 mo/ Hx/ c) (Fig. R01). 
 
age treatment genotype mean S.E.M. 
     
8 mo Nx tg 0.45 0.08 
  wt 0.40 0.11 
 Hx tg 0.90 0.04 
  wt 0.84 0.04 
14 mo Nx tg 0.50 0.03 
  wt 0.50 0.04 
 Hx tg 0.86 0.07 
  wt 0.86 0.12 
 
Tab. R01: HCT values of the experimental groups. 
 
 
Fig. R01: HCT increases as response to the hypoxic stimulus in animals of all ages. 
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Animals exposed to hypoxia showed an increased HCT, indicating increased erythrocyte 
production to secure oxygen supply throughout the body (transgenic and control animals of 
all ages pooled; 0.86± 0.07 for hypoxic conditions as compared to 0.46± 0.07 for controls, p< 
0.0001, Student’s T-test) (Fig. R02).  
 
 
Fig. R02: Pooled HCT and weight loss, normoxia vs. hypoxia. HCT is elevated in animals under hypoxia (H), as 
is weight loss (normoxia, N) (p< 0.0001, Student's T-test). 
 
The weight loss in percent of the weight at the start of the treatment, although highly variable 
between samples within each group, confirms that hypoxic treatment puts significant stress on 
the animals (18.9± 10.7 % in Hx compared to 3.2± 5.3 % in Nx, p< 0.0001, Student’s T-test) 
(Fig. R01 and R02). 
Summarizing these findings, hypoxia has a measurable effect on the treated group, and 
transgenic and control animals do not differ in their response as far as the chosen parameters 
are concerned. 
 
3. Histology confirms the effect of the hypoxic treatment 
Changes under Hx also occur within the structure of the brain. Most importantly, new vessel 
formation is triggered through an increased shedding of VEGF by vascular endothelial cells, 
amongst others (see introductory chapter). Histologic sections were prepared to evaluate this 
process known as reactive angiogenesis and to evaluate other potential tissue characteristics 
such as cerebral infarctions. The latter are known to correlate with increased blood viscosity, 
i.e. HCT. Furthermore, the question was raised, whether the modified hemodynamics could 
cause hemorrhages. To discard this possibility, brain slices were randomly chosen from both 
groups of different positions in the brain. These were stained with Prussian blue, also known 
as Berlin blue stain, a method that marks free iron (Fe2/3+) through a bright blue colour. This 
iron becomes liberated when erythrocytes loose their integrity through extravasation or in the 
clotting process (Fig. R03-05). 
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Fig. R03: Histology of an 8 month old, wild- type animal under hypoxia. On the left, cells are marked blue as a 
sign that they contain free iron (arrows in B). In the hippocampus, a vessel is occluded, possibly because of 
altered hemodynamics under hypoxia (arrow in D). Prussian blue stain. Scale is 50 and 200 µm respectively. 
 
 
Fig. R04: (A-C) Stained cells surrounding a vessel (arrow in A), at variable levels of the z- axis, to illustrate the 
cellular character of the stained structures (arrows in B, C and F). From the staining, only small areas are 
affected (D, marked is a portion of the olfactory bulb), with stained cells surrounding vessels and lying in groups 
of only several cells (E, F with arrow). Scale is 200 (D), 150 (E) and 50 (A-C, F) µm. Prussian blue stain. 
 
Angiogenesis was very prominent in the animals under Hx troughout the brain. It was 
especially developed in the vasculature within the cortex and surrounding the hippocampus 
(Fig. R05).  
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Fig. R05: Physiologic response to a hypoxic stimulus. Prominent reactive angiogenesis (arrows) in the cortex 
(CX) and in the hippocampal formation (gyrus dentatus, HC) under hypoxia (H) but not under normoxia (N). 
Prussian blue stain. Scale is 500 µm. 
 
Small stained areas were found across 8 and 14 month- old animals, wild- type and 
transgenic, under hypoxic treatment in the sections sampled, without any quantitative 
difference between them, as was assessed by observation (data not shown) (Fig. R03-05). The 
regular behaviour of the animals in all groups, including the ones treated with normoxia, 
confirms this as a minor finding. Major clotting or hemorrhages would result in clinical 
impairment and behavioural change. Minor alterations included clotting of small vessels (Fig. 
R03). Blue stained cells were also found present (Fig. R03, R04A-C). They most likely 
correspond to the macrophages/ microglia linage as this cell type is able to internalise free 
iron- containing blood particles through phagocytosis. This blood might have leaked from 
vessels that lost their integrity through clotting. The fact that blue stained cells were found 
only in groups and only surrounding vessels supports this interpretation of the findings (Fig. 
R04). Double- labelling studies would be necessary to assess whether these cells are in fact 
microglia. Further identification of this cell population was not carried out, because no 
information was to be gained from this which would have helped our working hypothesis.  
 
4. Plaque load is not significantly affected by hypoxic treatment 
Now it was asked whether hypoxia could change the A!- protein quantity in the brain. This 
was assessed in two ways: First histologically, by staining for A!- protein depositions, known 
as plaques and second quantitatively, as plaque load. The antibody used only stains solid and 
not diffuse plaques (Fig. R06). The latter refers to plaque- like structures of which the exact 
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boundaries are hard to assess due to their diffuse nature and pattern. However, the exact 
distinction between diffuse and solid plaques is not well defined. Histologically, diffuse 
plaques are not easily or reliably quantifyable, which is why it was decided to focus on the 
solid plaque load in histology. However, histology would only allow to quantify visible 
structures. To circumvent this restriction, the concentration of A!1-42 protein in the brain 
was measured using an ELISA approach.  
 
   
Fig. R06: Histology of an 8 month- old, transgenic animal under normoxia. A!- plaque (left) stained with anti- 
A!1-42, which marks only solid plaques. Microglial cells (right) presenting an unstimulated phenotype with the 
"arm's length" spacial distance between each two cells. 
 
Brain slices for histologic quantification were chosen in the following manner: After fixation 
and having been sectioned at 20 µm coronarilly, sections were screened as to where the 
hippocampus first reaches the ventral brain surface. In addition, two sections before and after 
this point were also chosen, with an inter- sectional distance of 260 µm. Sections from hereon 
were quantitatively assessed by projection onto a computer screen, where image manipulation 
was feasible. If there was any doubt about a given structure, the image was directly assessed 
through the microscope.  
In each of the selected sections, a part of the hippocampal formation known as the dentate 
gyrus was delineated with a corresponding selection tool (CAST statistical quantification 
software package). This anatomical structure was chosen on the grounds that it is easily and 
reproducibly identifyable within all sections of interest and that it has a reasonable size for 
quantification. Furthermore, as a part of the hippocampus, it is one of the areas known to be 
affected most by AD. The distribution of deposited plaques within this anatomical structure is 
not homogeneous, so a total of 100 % of the area selected had to be quantitatively assessed by 
plaque count, in order to obtain reliable results with acceptable deviations for the same 
sample being quantified (data not shown). The CAST software provides an algorithm, which 
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assures, that multiple image details (high magnification) represent 50% of the structure of 
interest (delineated with a low magnification). Again, the size of the dentate gyrus was crucial 
to keep the time spent on each quantified section within reasonable boundaries. The image 
details were photographed, summing up to and covering 50% of the area of interest, i.e. the 
dentate gyrus.  
Because it would not have been feasible to count the number of A!- plaques manually in such 
a large area, the Image J image analysis software was employed for quantification. Interest 
lied in two parameters: the total number of A!- plaques, and the area in percent that these 
depositions represent within the whole area of interest. The reasoning behind the latter is that 
it allows an estimation of average plaque size when the total number of plaques is taken into 
account. For example, if the total number of plaques has the same value for two groups, but in 
one group, the area that those plaques represent (in %) is bigger, then it can be argued, that 
the average plaque must also be of a larger size. 
Visually, no difference was observed between groups under hypoxia and normoxia, as 
illustrated by Fig. R07. What can be seen is that the plaque deposition between 8 and 14 
months of age is very progressive, which is especially true for the delineated anatomical 
structure of the dentate gyrus. 
To our surprise, no significant differences in A!- protein load were found: Comparing the 
number of plaques in 8- month old animals under hypoxic conditions with those of their 
control littermates, did not reveal significant differences (35.2± 9.9/ mm% in Hx against 29.3± 
4.2/ mm% in Nx, p> 0.05, One Way ANOVA/ Tukey). Since the total number of plaques was 
not altered by hypoxia, it was asked, whether the mean size of the !- amyloid (A!) 
depositions was modified. For this the percentage plaque area was determined, as has been 
explained above. Similar to the total number of plaques, no significant difference in the area 
of A!- protein depositions was found (0.90± 0.20 % in Hx against 0.91± 0.25 %, p> 0.05, 
One Way ANOVA/ Tukey). It can thus be argued, that neither the total number of plaques, 
nor their mean size changes under hypoxic treatment in 8- month old (transgenic) animals  
(Fig. R08A, B).  
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Fig. R07: (A-D) No altered amyloid deposition under hypoxic treatment in the hippocampal dentate gyrus. 
Visually, no difference in plaque deposition between Nx and Hx can be observed in either age group. Sections 
stained with antibody against A!1-42, scale 500 µm, N: normoxia, H: hypoxia, numbers indicate age [mo]. 
 
Surprisingly, for 14- month old animals, the same holds true: No significant alteration in 
number (74.8± 7.4 in Hx compared to 61.1± 4.6 in Nx, p> 0.05, One Way ANOVA/ Tukey) 
or percentage plaque area (1.72± 0.27 % in Hx against 1.48± 0.27 % in Nx, p> 0.05, One Way 
ANOVA/ Tukey) was detected (Fig. R08A, B).  
 
Fig. R08: Histology shows that neither the total number of A!- plaques (A) nor the occupied area (B) (and by 
extension their mean size) differs between N and H groups of either age group. Bars indicate mean values, dots 
individual ones. (C) ELISA reveals equal A!- protein loads for normoxia (N) and hypoxia (H) treated animals of 
14 months. 
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To confirm this observation, the A!1-42 peptide was quantified, i.e. the exact same protein 
that had been marked histologically, employing an ELISA. Animals of 8 months of age 
presented similar amyloid loads (0.41± 0.11 µg/mL under Hx against 0.47± 0.08 µg/mL under 
Nx) as did 14- month old animals (1.93± 0.33 µg/mL under Hx compared with 2.22± 0.21 
µg/mL under Nx). No significant difference in A!1-42 load was found within the age groups 
(p> 0.05, One Way ANOVA/ Tukey), confirming the histologic observations (Fig. R08C). 
Summarizing these findings, it can be stated, that hypoxic treatment does not alter the A!1-42 
protein load in the brain, neither in young nor old animals, as assessed both, histologically and 
by total ELISA quantification of A!1-42 protein. 
 
5. Oligomer formation under hypoxic treatment  
Since hypoxia did not alter the quantity of the A!- protein, it was asked whether it influenced 
it qualitatively?  
As described in the introduction, A!- protein does self- accumulate in various grades of 
complexity, i.e. as monomer, oligomer or fibril. Since oligomers are known to be the most 
neurotoxic "species" of the A!- protein, it was hypothesized, that under hypoxic treatment 
their quantity could increase. This change in the spectrum of the A!- species could, without 
any change in total A!- protein load, lead to increased neurotoxicity in animals under 
hypoxia. 
An antibody that recognizes various forms of oligomers, amongst them the A!- oligomer, was 
employed. Although somewhat unspecific, this is in our view the best method to assess 
oligomer quantity. The problem with methods such as classical SDS- PAGE and subsequent 
Western blotting is that the protein conformation is not kept intact but rather denaturated 
throughout the process. But an intact conformation is essential in order to evaluate aggregated 
A!- protein monomers, i.e. oligomers.  
Initially a dot- blot was employed, leaving the protein conformation intact and in its original 
state. The question was whether hypoxia could enhance oligomer formation. It was possible 
to visualize that there is a quantitative increase in oligomers under hypoxia (Fig. R09A). 
Since the sample size in this initial experiment was two in each group, statistics could not be 
applied. 
A try to reproduce these results in a native PAGE and subsequent Western blot was 
undertaken, employing a gel concentration of 16% to capture A!- monomers, which have a 
low molecular weight (4.7 kDa). Again, this methodology left the native conformation of 
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aggregated monomers, i.e. oligomers, intact. It was found that the amount of oligomers seems 
to increase under hypoxia (Fig. R09B).  
Future research is necessary to assess these preliminary findings more thoroughly. However, 
there is a trend towards enhanced oligomer formation under hypoxia. 
 
Fig. R09: (A) Dot blot with the oligomer antibody (A11), which (amongst others) marks A!- oligomers. 
Apparently, animals under normoxia (N) have lower quantities than their littermates under hypoxia (H). (B) 
Native Western blot with anti- A!1-42 antibody (6E10). At the bottom the monomer (4.7 kDa, double arrow) is 
marked, with the next band towards the top weighing around 12kDa (three- monomer- aggregates, single arrow) 
and classifying as oligomer. A trend could be suggested, with hypoxia increasing the oligomer quantity. 
Interestingly, two monomers do not aggregate. 
 
6. Microglia under hypoxic conditions  
It was asked, whether hypoxia alters the cellular response to the protein. Microglial cells have 
been described  as the first cells to encounter the A!- protein "threat" in the shape of plaques, 
i.e. A!- protein aggregates. They then try to encapsulate and subsequently degrade them (see 
introduction, 4.), which is illustrated in Fig. R10. Therefore, attention was placed on this 
population. 
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Fig. R10: Microglial cells encountering A!- plaques. In the left image, multiple Iba- positive, microglia cells 
surround a plaque. In the right image, one Iba- positive cell internalizes a plaque. In general, microglia move 
towards plaques to limit their expansion and degrade A!- protein. Microglial cells (red, anti- Iba1), plaques 
(green, Thioflavin-S stain), nuclei counter stain (blue, DAPI).  
 
Again, 8 and 14 month- old animals were selected for the experiments. Sections were selected 
qualitatively and quantitatively as described under 14. in the materials and methods chapter. 
In short, 50% of the area (hippocampal dentate gyrus) was randomly selected, the cell number 
quantified using the CAST software with its cell counting tools. The reduction in the sampled 
area compared to the plaque- quantification (100%) was feasible, because microglia are much 
more homogeneously spread across the dentate gyrus. The microglial cell linage was marked 
using an antibody against Iba1, a surface co- receptor, which in the brain is exclusively 
expressed in this cell-type (Fig. R10). The total cell count of microglia in the hippocampal 
dentate gyrus (hereafter simply referred to as total cell count) was calculated as was described 
under 14. in the materials and methods chapter. 
There are several factors that influence the amount of microglia in the brain tissue, namely 
genotype, age and hypoxia. First, transgenic animals are observed to have a larger microglial 
population than their wild- type littermates (Fig. R11 an Tab. R02). This is attributable to the 
fact, that the former group, through expression of the A!- protein, has an inherent 
inflammatory stimulus present. This stimulus induces microglial activation, examplified by 
Fig. R12, and also leads to larger numbers of microglia present in the brain tissue (compare 
Fig. R13A to B for 8 month old animals and R13C to D for 14 months). 
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Fig. R11: Total cell count of microglia in the hippocampal dentate gyrus in wild- type (wt) and transgenic (tg) 
animals under normoxic (Nx) and hypoxic (Hx) treatment. Total, Iba1- positive cells were assessed for the whole 
hippocampal gyrus dentatus, with a sampled area of 50% of the gyrus area. Note, that in general, transgenic 
animals, especially at 14 months, present with a higher microglia cell count than their wild- type littermates. 
Multigroup comparison reveals a significant decrease in the microglia cell count in "tg 14" animals under 
hypoxia (asterisk indicates a significance of p< 0.05, ANOVA/ Tukey). Single group comparison reveals a 
significant decrease of the microglia cell count for "wt 14" animals under hypoxia (p< 0.01, Student's T- test).  
 
 
age type treatment Iba1+ cells (mean) S.E.M. 
     
8 wt Nx 941 183 
  Hx 1002 169 
 tg Nx 1409 121 
  Hx 1139 92 
14 wt Nx 1359 15 
  Hx 962 63 
 tg Nx 2633 178 
  Hx 1963 254 
 
Tab. R02: Values from the graph in Fig. R12. Iba1- positive cells are microglia. 
 
   
Fig. R12: Activation of microglia leads to a change in phenotype. Images are taken from two animals, one 8 
months, wild- type (left) and one 8 months, transgenic (right), both under normoxia. An unactivated, surveilling 
microglial cell (left) is characterized by long processes and stays at an "arm's length" distance from any 
neighboring microglial cell. Activated microglia (right) loose their processes and have an increased cytoplasm- 
nucleus relation. Also, the homogenous positioning in the context of neighboring microglial cells is abandoned, 
and various cells can be found within a small area (see also Fig. MM01).   
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Second, the total number of microglia cells increases with age (Fig. R11 and R13). This is 
especially true for transgenic animals, where the number of microglia nearly doubles in a six 
month period, i.e. from 8 months to 14 months (compare Fig. R13B to D). However, an 
increase in microglia is also visible for wild- type animals (compare Fig. R13A to C). 
Third, the total number of microglia cells decreases under hypoxia in old animals (Fig. R11, 
13 and Tab. R02). Visually this can be assessed by comparing old, hypoxic animals in Fig. 
R13 (H, 14) to their normoxic controls (N, 14). The image in the latter gives the impression of 
a more disperesed microglia population, through which the staining appears less intense. 
When quantified, this difference holds true. Multigroup comparison reveals a significant 
decrease in the total number of microglia in the gyrus dentatus of old, transgenic animals 
under hypoxia (Fig. R11, asterisk indicates a significance of p< 0.05, ANOVA/ Tukey). None 
of the other groups reaches significance under a multigroup comparison. However, when 
observing the graph in Fig. R11, the difference in the number of microglia seems substantial 
for old, wild- type animals also. This observation reaches significance through a single- group 
comparison (p< 0.01, Student's T- test). However, future reasearch should increase the sample 
size to gain more statistical certainty. 
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Fig. R13: Microglia in animals of different genotype (transgenic [tg], wild-type [wt]), of different age (8 and 14 
months) and under different conditions (normoxia [N], hypoxia [H]). Marked (string line) is the hippocampal 
dentate gyrus, from which a sample area of 50% was chosen to quantify microglia in (compare graph in Fig. R11 
and numbers in Tab. R02). Scale 500 µm. Paraffin sections stained for Iba1, a microglia marker (brown colour). 
In tg animals the typical microglia behaviour of grouping around A!- plaques can be observed (arrows).  
 
 
Summarizing, it can be stated, that the total number of microglia in the hippocampal dentate 
gyrus, and, it can be argued, by extension the brain, changes dynamically with various factors. 
 44 
First, transgenic animals present an increase in microglia. Second, microglia increase with 
age. Third, microglia decrease under hypoxia, but only do so significantly in old animals. 
 
7. Correlation between the number of microglia and vessel density  
As microglial cells were found to be diminished in the oxygen- deprived group, it was asked, 
whether this absence correlated with vessel density. The latter is a constraint on how much 
oxygen can be transported into a specific region. So it was hypothezided, that the number of 
microglia per mm2 plaque, as had been assessed previously, correlated with the regional 
vessel density. The reasoning behind this approach is the fact, that microglia are dependent on 
oxygen, which reaches them through blood vessels and subsequent diffusion through the brain 
tissue. This raises the following question: Does less oxygen supply as estimated by vessel 
density correlate with less microglia per mm2 plaque?  
A triple staining technique was employed, which includes staining for Iba1 (microglia), an 
unspecific secondary IgG anti- mouse antibody to reveal globulin structures (vessels), and 
finally super- staining with Thioflavin-S (plaques). The somewhat unorthodox staining of 
mouse brain vessels was necessary, due to the absence of potent antibodies. However, the 
staining results were beforehand correlated with a hematoxylin- eosin (HE) stain, and the 
vessel staining capacities of the unspecific secondary antibody were deemed acceptable for 
our purpose. As for animal selection, 14 month- old animals of both groups, normoxia and 
hypoxia, were pooled. This augmented the sampled areas. Furthermore, a distinction 
according to treatment was not necessary under the question posed. The number of vessels 
was determined with the help of a randomly- oriented, multi- circular form, included in the 
CAST software. The number of crosses of vessels with the lines of this form was counted, and 
taken as the parameter for vessel density. This methodological approach draws on Cavalieri's 
principle. According to it, two bodies have the same volume, if their cut surfaces, in planes  
parallel to a ground surface, have the same area. 
The number of Iba1 positive cells per 100 µm% plaque area was determined, with the same 
technique as had been used before. Then, this value was correlated to the number of vessels in 
the respective plaque's perimeter. As shown in Fig. R14, a positive correlation was found 
between the number of microglial cells and vessel density. More microglial cells were present 
when more vessels were found (R% = 0.16, Pearson Correlation Test, 2 Sides p = 0.002).  
It can be deduced, that although microglial cells have been shown to be resistant to hypoxic 
stimuli, they are dependent on adequate oxygen supply in the long run. If this supply does not 
meet the cells' needs, the capacity to confront A!- protein depositions is compromised. 
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Fig. R14: Correlation between Microglia per plaque with vessel density. Statistics: Pearson- Correlation- Test, 2 
Sides, (p< 0.01).  
 
8. Cultured microglial cells respond with increased viability to hypoxic stimuli 
In order to analyze whether hypoxia influences cell viability of microglia, cell culture 
experiments were performed with microglia- enriched primary cell cultures. 
These cell cultures were exposed to hypoxia and the effect on cell viability evaluated using 
and XTT assay. Exposition to 1 % oxygen was for 4, 24 and 48 hours. Under 24 and 48 h of 
hypoxia, cell viability was detected to be significantly increased, compared to cells cultivated 
under normal oxygen conditions (24h: relative O.D. 1± 0.04 in Nx versus 1.25± 0.09 in Hx, 
Student’s T-test p< 0.01; 48h: relative O.D. 1± 0.04 in Nx against 1.35± 0.07 in Hx, Student’s 
T-test p< 0.001; 3 repetitive experiments respectively, results pooled, then analyzed). 
However, no significant difference was detected after 4h of exposition to the hypoxic stimulus 
(relative O.D. 1± 0.05 in Nx compared to 0.95± 0.05 in Hx, Student’s T-test p= 0.45) (Fig. 
R11).  
It can be deduced, that the microglial loss does definitly not occur in the short- term, but that 
it is most likely due to the prolonged exposition to hypoxia. Accordingly, microglial cells 
must disappear at later stages of exposition to oxygen deprivation. 
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Fig. R15: Microglial cell viability after 4, 24 and 48 hours of hypoxic exposion. Two stars mean p< 0.01, three 
p< 0.001. No significant difference after 4 hours, but increased viability of cells under hypoxia compared to 
normoxia after 24 and 48 hours of exposition. 
 
9. Plaque occupancy under hypoxia 
One of the important mechanisms in controlling the A!- protein depositions is the microglial 
function to surround a plaque, restrict its extension, minimize the plaque's reactive surface, 
and ultimately attempt to degrade it. With the finding of less microglia under long- term 
hypoxia, we wondered whether the function of microglia was compromised in the hypoxia 
group. A significant decrease in the total number of microglia in the hippocampal dentate 
gyrus due to hypoxia was only found in 14 month- old, transgenic animals. Therefore it was 
decided to focus only on this group.  
A parameter called "plaque occupancy" was coined, to assess the microglia function to 
confront A!- plaques. Plaque occupancy is defined as the number of microglia in spatial 
proximity to one square millimeter of A!- plaque. This means, that microglia restricting one 
plaque are counted, and then normalized to this plaque's area. It was hypothesized that 
hypoxia would decrease plaque occupancy. This was supported by visual findings as 
exemplified in Fig. R16. 
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Fig. R16: Detailed view of microglia with the typical accumulation around A!- plaques. Dentate gyrus of 14 
months old, transgenic animals. Scale 500, 200 and 50 µm. Magnifications 100, 200 and 1000, respectively. Less 
microglia are present under hypoxia (H) than normoxia (N). Triple- stain: Anti- Iba1 and HE counterstain, to 
show microglia and nuclei under white light (left image of N and H, respectively) and Thioflavin- S stain to 
show plaques under UV- light (right image of N and H, respectively). 
 
 
As described under 14. in the materials and methods chapter and illustrated in Fig. MM05, 
plaque occupancy was assessed in the following way: Randomly chosen plaques from 14 
month- old animals were selected, with a representative number of plaques for each animal 
and in normoxia and hypoxia (in total 176 plaques). Subsequently, the plaque area was 
determined and the microglia present around the plaque were counted (Fig. MM05A and B), 
with plaque occupancy being calculated thereafter (Fig. MM05C and D). Then, the obtained 
values were pooled across animals in the respective groups, namely normoxia and hypoxia. 
This quantitative analysis revealed a significant drop in plaque occupancy in old animals  
under hypoxia (Fig. R17). Under normoxia, 46.24± 4.41 (mean± S.E.M.) Iba1- positive cells 
surround 1 mm2 of plaque area, but only 20.87± 4.27 cells are present under hypoxia 
(Student’s t-test, p< 0.01). 
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Fig. R17: Plaque occupancy, i.e. number of microglia per mm2 of A!- plaque. Plaque occupancy significantly 
decreases in old, transgenic animals under hypoxia (H, normoxia N) (asterisks indicate a significance of p< 0.01, 
Student's T- test). 
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Discussion 
 
1. The hypthesis 
It is known that increased severity of Alzheimer's disease (AD) is associated with hypoxic 
conditions of the brain tissue, such as stroke (Schneider et al., 2007; Snowdon, 2003). 
Furthermore, various vascular risk factors are associated with AD (see introduction). 
Considering this, it was asked whether hypoxia could alter the progression of the disease, in 
the sense that there is a direct and causal relationship. 
We will start by evaluating the model and the methods that were used to answer this question. 
In the following part, the obtained results will be reflected and discussed in the context of the 
literature.  
 
2. The model 
There are three alternative models to study AD. First, the direct study in humans. This 
approach delivers the most valid results. However, it is limited. Post- mortem histologic 
examination of the brain poses no ethical dilemma. But to deliberately cause hypoxic brain 
conditions in the living subject does, and is not an option.  
The second model employs cell cultures. The advantage here lies in the possibility to control 
many factors of the experiment. But the results are not as valid as in vivo findings. 
Furthermore, AD poses a complex network of a myriad of partly unknown, interacting 
factors, such as the behaviour of cell populations.  In vitro experiments would not be suitable 
to study this complexity. It is only after singling out a specific factor to study that cell cultures 
are an appropriate choice as a model. 
The third model to study AD is the use of murine, transgenic animals (Borchelt et al., 1997), 
as has been done in the present study. However, caution must be taken when translating the 
results into the human context (and by extension the clinical setting), as it is unlikely to 
capture its every nuance. The model's advantage is the possibility to expose animals to 
hypoxic conditions in order to study the effect on AD progression. There are, however, flaws 
in this model and this particular experimental approach. The murine model of AD only 
mimics the disease. It sets out from the rather simplistic view that the main pathology in AD 
is the deposition of A!- plaques. There are two problems with this assumption.  
First, the description of the disease is far from complete, with many pathologic processes 
occurring in parallel and at different times. A complete understanding of the interactions of 
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these processes is yet not reached. There are certain theories that intend to unify the known 
facts, such as the amyloid- cascade theory described earlier (see introduction, 1.3.3) (Selkoe, 
2002a). But at the time of writing, there is no consensus of what is "the main problem" with 
AD (Korczyn, 2012). Propositions as to the cause of AD span from accumulation of !- 
amyloid and subsequent synaptic dysfunction (Selkoe, 2002a), pathogens (Miklossy, 2011), 
neurovascular pathology (Zlokovic, 2011), convergent pathogenic pathways shared with other 
neurologic diseases (Ehrnhoefer et al., 2011), mitochondrial dysfunction (Eckert et al., 2011) 
etc. This is why a model that concentrates on one characteristic is necessarily simplistic and 
only a variety of models can depict the complexity of the disease (Guerreiro et al., 2011). 
The second flaw of the model is this: Human APP and thus human A!- protein are expressed 
in a murine organism. However, it seems that the protein "behaves" similarly as in humans, 
e.g. aggregating and leading to neurodegeneration. But it is unlikely that the organism's 
response to the externally inserted protein is the same as in humans. The immune system of 
humans and mice vary to some degree, and so does a myriad of possible other implicated 
structures. The interaction between A!- protein and the mouse's organism is likely to differ 
compared to humans. 
The experimental approach needs further attention. Hypoxic tissue conditions in the brain 
were mimicked in a practical but simple manner. This was done by exposing the animals to 
hypoxia, both terminally (i.e. it lasted until the animals were sacrificed) and continuously, in 
an especially designed chamber. The animals were not let to adapt to hypoxia in a gradual 
introduction scheme, instead the stimulus was presented abruptly. The property that was did 
not mimicked closely was the local restriction of hypoxia in brain tissue, as the stimulus was 
applied to the whole animal. However, it can be theorized that any influence a local hypoxic 
stimulus might have, a general one would have nonetheless, only more prominently and thus 
more easily detectable. Furthermore, this approach of general hypoxia has been used by 
others (Sun et al., 2006; Li et al., 2009).  
 
3. The variables 
A large number of variables exists that could potentially be measured to assess the effect of 
hypoxia on AD. Classically the amount of A!- deposition and Tau- tangles are estimated. 
However, our murine model does not develop the latter. Also the activity, translation and 
expression of the enzymes and cofactors that jointly manufacture APP into A! could be 
assessed. Apart from this, various cell populations could be examined, e.g. by cell count or 
assessment of their expressional profiles. This enumeration is only meant to illustrate the 
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variety of possible approaches and by no means complete. It was decided to concentrate on 
three variables to measure the effect of hypoxia on AD progression.  
First, there is the A!1-42- protein, known to be the A!- isoform associated with the most 
detrimental disease progression (Rauk, 2008). Its quantity was determined through histology 
and ELISA. Secondly, a try was undertaken to estimate its structural quality by assessing the 
amount of A!- oligomers present. And third, the organism's response to the A!- protein 
stimulus was investigated with the focus on microglia, in both histology and cell culture. 
 
4. The results 
4.1 Hypoxia induces response 
First it was demonstrated, that hypoxia induced a systemic response in the animals exposed to 
it. The hematocrit (HCT), i.e. the percentage of the concentration of red blood cells in blood, 
is known to increase under hypoxic conditions. As assessed by HCT there was a significant 
difference between hypoxic animals and those exposed to normoxia. Visually, animals under 
hypoxia presented with extensive angiogenesis in histology, but this was not quantified. The 
observed behaviour of the hypoxia group did not differ from controls apart from the fatigue 
due to this unphysiological stimulus, without observable neurologic deficits. A point of 
possible critique is that this was not consistently quantified nor recorded. However, the 
histologic sections were analyzed for strokes or hemorrhagic insults due to increased HCT in 
the hypoxic animals, but no indication of pathologies could be found. 
 
4.2 Hypoxia and A!- quantity 
Hypoxia has been linked to increased levels of A!- protein accumulation (Zhang et al., 2010). 
Accumulation can be achieved in three different ways: increased production, decreased 
degradation and slowed down clearance.  
This is supported by various findings reported. In post- mortem samples of human AD brains 
following ischemia, APP levels are elevated (Pluta et al., 1998). As another piece of evidence, 
it was found that BACE1, the APP cleaving enzyme !- secretase, has a HRE (HIF- responsive 
element) in its promoter region, and is upregulated under hypoxia in vitro and in vivo in a 
mouse model (Sun et al., 2006; Zhang et al., 2007). Sun et al. also demonstrated that in a 
murine mouse model of AD, hypoxia caused an increase in A!1-42. Another group was able 
to confirm this  (Li et al., 2009). To our knowledge, these groups present the only evidence 
that A!- protein accumulation increases under hypoxia in vivo. 
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In the experiments carried out by us, it was not possible to reproduce these findings. 
Histology and ELISA were employed to determine A!- quantity. None of these methods 
showed a significant difference in A!- plaque or A!- protein load. This is true for 8 and 14 
months old animals.  
How can this discrepancy be explained? Although seemingly similar, the approaches pursued 
by Sun et al. and Li et al. differ from our one in important aspects. All approaches used 
histology and plaque analysis as well as ELISA to determine A!- protein quantity. But some 
possible sources of bias can be detected in the two articles cited: 
Sun et al. used a different murine AD model, which reduces the comparability to our study. 
The animals used were 8 months old, which is not a senile age for this species. 8 month- old 
animals were employed too, but were so as a longitudinal reference point to assess the 
temporal development of the variables under investigation, e.g. plaque load. However, 14 
month- old specimens were also analyzed, an age, that is more representative of senesence in 
mice. Furthermore, this mimics more closely the conditions found in humans. Sun et al. leave 
aside this context of old age.  
Their counting method for plaques stained in histology is also not beyond criticism: The 
investigation did not concentrate on one reproducibly identifiable region of the brain for 
plaque analysis. The hippocampus and its substructure the dentate gyrus were selected, as this 
has been known as a severely affected structure from AD pathology (Borchelt et al., 1997; 
Sabuncu et al., 2011; Braak et al., 1993a/b; Schousboe et al., 1993). But besides the advantage 
of analysing a knowingly affected structure of the brain, it makes it also possible to analyse a 
higher percentage of that structure. The dentate gyrus was sampled in 5 sections per animal, 
and 100% of each section was analysed for plaque number and area. Extrapolation from these 
data is more robust than had one analysed the whole brain at a low sampling rate, e.g. one 
percent. This is in fact what Sun et al. did. In their approach 10 sections cover the whole 
brain, without reference to which anatomical structures these sections include and to what 
degree the respective structures are affected by AD pathology.  
Furthermore, their histologic parameter for A!- quantity is plaque number only. Counting 
plaques by hand is not as reproducible as employing an automated method. No comment is 
made in the article as to size and staining intensity thresholds, which is important when one 
wants to determine what to count as a plaque and what not, eventually adding bias. Another 
point of critique here is that "number of plaques" is alone not a precise measurement for A!- 
quantity. Hypoxia could hypothetically change the property of the A!- protein, so that it 
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accumulates in smaller plaques, without any modification of the total A!- quantity. That is 
why the measurement "plaque area" was employed additionally by us.  
Sun et al. used a different method of exposing the animals to hypoxia. The hypoxia group was 
put into a hypoxic chamber for 16 hours each day, for a total of one month. This procedure is 
unsuited. For one, it does not mimic the nature of ischemic brain conditions as in stroke, 
which do not fluctuate in this way. Secondly, a myriad of adaptive mechanisms related to 
hypoxia is continually "turned on and off", such as stress at exposure. In our model, after a 
stressful initial period of hypoxic exposure, the animals were left to adapt to this new 
stimulus. This is also why the validity of the behavioural experiments Sun et al. performed to 
assess spatial memory deficits employing Morris' water maze can be criticized. They found a 
significant reduction in spatial memory in the hypoxia group and attribute this to the hypoxic 
treatment (Sun et al., 2006). As a further point of critique, the normoxia control group was not 
put in a chamber without the hypoxic stimulus. What this implies is that the behaviour of the 
hypoxic mice was conditioned towards fear, as they expected suffocation every time they 
were taken out of the cage. This could possibly alter their behaviour in any behavioural test, 
without the necessity of there being a structural deficit in the brain. However, the stress which 
the animals experience in the hypoxia experiments comes mostly from hypoxia itself. 
"Intrinsic" stress that stems from the respective protocols and procedures, such as conditioned 
fear, is additional.  
The ELISA employed by Sun et al. did not quantify the A!- protein load in the animals, but in 
cell cultures, making the result not comparable in validity to our ELISA from brain samples. 
Li et al. took a similar approach to Sun et al.: The animals' age and the hypoxia exposure 
procedure were similar to conditions in the experiments of Sun et al.. Their control group has 
also not been put into the chamber construction, to be exposed there to normoxia. Again, the 
additional stress associated with the chamber construction and the handling of the animals 
therein has not been controlled for in both groups, normoxia and hypoxia, but occured only in 
the latter. This methodological flaw might affect the experiments' outcome. Furthermore, their 
quantification procedure for A!- protein from histology is also whole- brain based and 
methodologically unclear (as concerns sampling areas, thresholds etc.). The ELISA is from 
brain tissue, but only the "lateral" part of a hemisphere. As discussed earlier, this sampling of 
the brain for either histology or ELISA without any anatomical basis makes the information 
obtained less robust. Whole hemispheres were sampled for the ELISA performed. 
In summary it can be stated that both articles discussed above show methodological flaws. 
With a continuous hypoxic exposure, with the control group receiving treatment in the same 
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chamber and with sampling of defined brain areas, there is no significant difference in the 
amount of A!1-42 protein detectable, neither in 8 nor 14 months old animals. 
However, there are other findings that have been described in vitro and also hint at an A!- 
protein increase under hypoxia, such as a HIF- binding site in the promoter region of APH-1, 
a constituent of the #- secretase cleavage enzyme (Wang et al., 2006). But so far and as to our 
knowledge, these findings were not reproduced in vivo. 
 
4.3 Hypoxia and A!- quality 
The appearance of A!- protein in the brain stretches from diffuse presence in the monomer 
form and self- association in oligomers to fibrils that are histologically recognizable as 
plaques (Rauk, 2008). Influencing the accumulation in a way thats hinders plaque formation 
has been under investigation, but so far it is not clear whether this is beneficial (Härd et al., 
2012; Kinghorn et al., 2006). Oligomers have been found to be the most neurotoxic A!- 
species (Larson et al., 2012).  
Initial experiments were carried out to address the hypothesis, that hypoxia leads to an 
increase in this particular A!- form, i.e. a shift in the spectrum of A!- self accumulation. It 
was found, that this was indeed the case for a small sample population. But for significant 
results, future experiments need to investigate this question more deeply. However, this poses 
an interesting direction of thought: If the overall quantity of A!- protein under hypoxic 
conditions is not altered, an increase in the oligomer- form could still lead to a more severe 
and rapid disease progression without affecting the net A!- amount measured. This would 
have important implications, as there are various attempts to correlate biomarkers, such as 
A!- and Tau- proteins in the cerebrospinal fluid (CSF) with the disease state, in order to 
diagnose AD with more precision and predict the disease's progression (Hansson et al., 2006). 
However, if the oligomer hypothesis is true, these attempts would possibly not be valid. 
 
4.4 Hypoxia and microglia 
Microglial cells play an important role in inflammation in the brain (Ransohoff et al., 2009). 
However, no consensus exists as to whether neurodegeneration results from too much or too 
little inflammation (Lucin et al., 2009), and the effects of inflammation on different cell 
populations can vary greatly (Covey et al., 2011). In addition, there is no common agreement 
whether microglial cells are active or reactive players in neuroinflammation, or even victims 
of it (Graeber et al., 2010). As already described in the introduction, this uncertainty arises 
from a large variety of microglial phenotypes and subclasses. Some phenotypes are highly 
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inflammatory and by extension neurotoxic (M1) and some are believed to be neuroprotective 
(M2), as has been described in detail for macrophages (Mantovani et al., 2004). 
 
 
Fig. D01: Illustration of expression profile of M1 and M2 macrophages. Adopted after Mantovani et al. 
(Mantovani et al., 2004).  M1 and M2 activational profiles are presented as extremes of a continuum. A 
subpopulation of microglia is placed on this continuum depending on it expressional profile, which is a 
consequence of specific stimuli. See also Fig. D02. 
 
 
M1 and M2 are the two extremes of a continuum (Fig. D01). A classification within this range 
is possible according to the expression of selected molecules, i.e. the gene expression pattern 
determines the polarisation (Mosser, 2003). The respective phenotype of a microglial 
subpopulation depends on the stimuli presented to it, i.e. its "milieu" (Fig. D02) (Lucin et al., 
2009).  
For example, A!- proteins have been demonstrated to induce a more neurotoxic phenotype in 
a microglial population (Jimenez et al., 2008). There are many mechanisms whereby 
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microglial cells are subsequently able to mediate neuronal death and thus AD progression, 
e.g. through the expression of iNOS (inducible nitric oxide synthase) (see also Fig. D02, 
"output") (Brown et al., 2010). 
 
 
Fig. D02: Diagram of the various characteristics of microglia. Adopted after Lucin & Wyss (Lucin et al. 2009). 
The various stimuli that can activate microglia into various profiles are depicted under "recognition". "Output" 
then differs accordingly. 
 
 
Hypoxia is associated with increased glial activation (Suk et al., 2004). In vitro, glial 
activation and hypoxia combined induce extensive neurodegeneration, but each condition 
alone does not (Mander et al., 2005). Glial activation through hypoxia occurs in vivo as well: 
In humans, PVWD (periventricular white matter damage) is a condition caused by hypoxia of 
the newborn. The associated neuronal damage is believed to result from hypoxia- mediated 
activation of microglia. Subsequently, this causes an increased production of inflammatory 
cytokines, free radicals and NO (Deng et al., 2011). With reference to Fig. D01, the 
implicated microglial phenotype could be described as M1. An activation of microglia has 
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further been found to be a key factor for progressive neurodegeneration by mathematical 
modeling of AD dynamics (Puri et al., 2010). 
The number of microglia in the hippocampus was counted as a measure of the quantity of 
inflammation. In the experiments it was found, that there was an increase in the number of 
microglia with age and with AD- pathology in the transgenic model. However, the number of 
microglial cells diminished under long- term exposure to hypoxia.  
In old transgenic animals under hypoxia, there was a significant decrease in the number of 
microglia, when compared to the normoxic control. A decrease in old wild- type animals 
under hypoxia was found as well, compared to their normoxia controls, although this was not 
significant. But by changing the statistical test from a multi- group test (ANOVA) to a single- 
group test (Student's T), the decrease did reach significance. One can hypothesize that with an 
increase in sample size, significance under the ANOVA- test is possible. To summarize this: 
Under hypoxia, the number of microglial cells decreases significantly in old transgenic 
animals as tested by ANOVA.  
Microglial cells are known to be involved in A!- protein clearance, for example through 
phagocytosis (Lee, 2010). A!- plaques attract microglia, which group around a plaque in 
order to limit its size and degrade it (Fig. MM01, reproduced from the methods & materials 
section).  
 
 
Fig. MM01: Iba1 stained microglia surrounding what appears to be a plaque, scale is 50 µm 
 
To assesses the microglia function to confront A!- plaques, a metric called "plaque 
occupancy" was coined. It is defined as the number of microglia in spatial proximity to one 
square millimeter of A!- plaque. It had been hypothesized that hypoxia would decrease 
plaque occupancy and it was possible to show, that it did so indeed: The number of microglia 
roughly halved after long- term exposure to hypoxia, when compared with the normoxia 
control group.  
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The decrease in microglia in the experiments has not been described in the literature. 
However, it is known that microglia respond to short- term hypoxia with activation (Suk, 
2004). To test this, murine microglia- enriched cell cultures were prepared (Saura et al., 
2003). It was possible to reproduce the finding, that microglial cells respond to a short- term 
hypoxic stimulus with increased viability as a measure of activation. Despite its limitations in 
representing the purely microglial reactions to external stimuli as they are in the real brain, 
namely due to the distortions from signalling of present astrocytes (Saura, 2007), it was 
decided to use this model, as it is more physiologic than the usage of an immortalized cell 
culture. A comparable exposure time as in the in vivo model was not feasible due to restricted 
survival of the cultures. Also, wild- type animals were used for the preparation of the cultures. 
It can be argued, that the result of increased microglial activity under hypoxia is nevertheless 
transferable to the AD model: In vivo, a decrease in the number of microglia under long- term 
hypoxia in wild- type as well as in transgenic animals could be observed. The behaviour of 
microglia was not qualitatively different in the two groups. It can be inferred that the results 
from cultured wild- type microglia can be translated equally to the transgenic animals. 
To summarize it was found, that microglial cells respond differently to hypoxia in the short- 
as compared to the long- term. Microglia cells are quite resistent to short hypoxic stimuli. It is 
known that microglia react to short periods of hypoxia with activation, which it was possible 
to confirm. However, if the hypoxic exposure is long- term, microglial cells decrease in 
number, and this correlates positively with vessel density and- it can be argued- oxygen 
supply. Thus, microglia appear not to be resistant to long- term oxygen deprivation. It can be 
argued, that microglial behaviour and resistance to hypoxia is a function of the time length of 
hypoxic exposure, and that it differs greatly between the short and the long run. 
 
4.4.1 A!- quantity is not altered by a decreased number of microglia  
Integrating the results so far: Under long- term hypoxia, the A!- quantity does not change 
(see 4.2 and 4.3), and the number of microglia decreases, compared to the normoxic control. 
However, one would have suspected the A!- quantity to increase given a decrease in 
microglia. 
This is particularly interesting since microglia are believed to play an important role in 
clearing A!- protein from the brain (Lee et al., 2010), although the exact mechanism is not 
known (Hawkes et al., 2012). Various other, non- microglia enzymes have been shown to also 
degrade A!- proteins (Miners et al., 2011). A!- degradation is thus not entirely dependent on 
microglia. However, a loss of clearing function might increase the A!- load, and this in turn 
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would aggravate AD- progression (Lemere et al., 2010), as even small increases in A!- 
quantity can change the disease's dynamics substantially (Puri et al., 2010). In a murine model 
of AD, A!- accumulations were almost completely cleared from around the area of induced 
focal ischemia in the brain, and this was associated with infiltration of microglia (Van 
Nostrand et al., 2012).  
Four explanations are proposed to the phenomenon of unchanged A!- levels despite a 
decreased number of microglia.  
 
1. First, although microglia internalize the A!- protein formations (Hawkes et al., 2012), 
it could be that they are not able to degrade them sufficiently (Simard et al., 2006). This has 
been demonstrated for the oligomer A!- form: microglia do react to A!- protein by 
activation, but the functions of phagocytosis and clearance are disturbed by it (Pan et al., 
2011). It can be argued that clearance takes place but is not effective in degrading A!- 
protein. Therefore, a decrease in the (deficient) A!- clearance rate through a decrease in the 
number of microglia would not lead to significant changes in total A!- load. That is, 
microglial clearance does not "work" to lower the levels of A!- protein, and thus less 
microglia have no effect on A!- levels. 
Interestingly, it has been reported that in murine AD- brains, A!- quantity does not increase 
overtly despite dysfunctional microglial cells (Mildner et al., 2011). This finding is backed by 
other groups: Meyer-Luehmann et al. reported that resident microglial cells are not involved 
in the formation of A!- deposits (Meyer-Luehmann et al., 2008). Grathwohl et al. showed that 
A!- plaque formation and A!- associated neural damage do not depend on microglial 
presence, in neither of the two murine models of AD assessed (Grathwohl et al., 2009).  
The role microglial cells play in A!- clearance remains disputed. However, the presented 
findings, from our own laboratory and from the literature, indicate, that this role is minor. 
Thereby, a decrease in the number of microglia and a subsequent decrease in the microglial 
clearance rate is likely not to affect the A!- quantity significantly.  
  
2.  Second, the remaining microglial cells could compensate functionally for the lost 
 ones, by upregulating proteins that are involved in their clearance function. Such 
thresholds are known from type- 1 diabetes and familial Parkinson's disease. Accordingly, if 
the number of functionally valid cells remains above a certain threshold, the function of the 
cellular population (insulin- producing !- cells of the pancreas and dopaminergic neurons of 
the substantia nigra, respectively), remains intact. The respective threshold examples are 20%  
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for type- 1 diabetes (Herold, Innere Medizin, 2011) and 30% for Parkinson's disease 
(Mumenthaler, Neurologie, 2008), meaning that this is the minimum amount of cells with 
which a sufficient function is possible.  
There is some evidence that thresholds exist for microglia: Mathematical modelling using 
data from the literature have yielded microglia density thresholds that are associated with A!- 
plaque formation (Luca et al., 2003; Quinlan et al., 2005). Surpassing the threshold, 
microglial density can predict plaque formation. However, due to uncertainty within the 
parameters of the model, there is a large variation in the microglial density. The variational 
range of microglial density encompasses levels found in both, AD patients and healthy 
subjects, limiting the use of the threshold value. 
Another study reports, that neurodegeneration occurs once 40% of the microglial population 
is activated (Rogove et al., 2002). However, caution is advised when interpreting this result. 
Here, microglia were artificially activated by the injection of the excitotoxin kainate into the 
murine hippocampus. First, this is not a physiologic stimulus. And second, the resulting 
activational profile of the microglia (M1) may lack validity. 
To summarize, the implication of this hypothesis is that if microglia dropped further in 
number and below an unknown threshold, which is likely to exist, the resulting loss of the 
clearance function would lead to detectable increases in the quantity of A!- protein. However, 
as has been mentioned above, it is questioned whether microglia presence is really necessary 
for A!- clearance.  
 
3.  Clearance of A!- protein from the brain may involve mechanisms, beyond those 
 related to microglia (Lee et al., 2010; Kurz et al., 2011). As the microglial number and 
the population's function to clear A!- protein drops, compensatory mechanisms may be 
activated, leading to an unaffected net A!- clearance. One mechanism to achieve this could be 
the upregulation of the receptor for glycosylated end- products (RAGE) which is located at 
the blood- brain- barrier (BBB) (Deane et al., 2009). Interestingly, RAGE has recently been 
shown to be upregulated under hypoxia (Tafani, 2011).  
 
4.  Forth, under long- term hypoxia, protein- synthesis of many proteins drops (Semenza, 
2011). It could be that the A!- protein synthesis actually drops due to hypoxia, resulting in 
lower levels of A!- protein. Besides the consideration of the sparse data on this topic (see 
4.2), and with the majority being in vitro studies, this hypothesis is not entirely off- ground, 
especially in the in vivo context. A reduced number of microglia and a subsequently lower 
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clearance rate would then not result in a detectable net change of A!- load, as the A!- protein 
synthesis drops also. 
 
4.4.2 The number of microglia decreases under hypoxia 
Two lines of reasoning are proposed to explain the decrease in the number of microglia under 
hypoxia. 
 
1. First, in neuronal cultures it has been shown that neither hypoxia nor A!- toxicity 
 affected cell viability to a great extent, but when combined, the two stimuli resulted in 
significant neuronal degeneration (Mander et al., 2005). It is proposed that microglia behave 
in a similar fashion. The cell population could be left unaffected by either hypoxia or A!- 
toxicity alone. But the combination of both could cause the microglia to diminish. As our own 
experiments in vitro demonstrated and in accordance with what has been demonstrated by 
others, microglia are activated by hypoxia (Suk et al., 2004). This activation poses a 
significant challenge to the cell, as many cellular processes are upregulated (Semenza, 2011; 
Eltzschig et al., 2011). If this activation lasts for a long time due to long- term hypoxia, and if 
combined with the inherent A!- toxicity of the animal model, the microglial cell population 
could simply "wear out". The stress imposed could reduce the microglial life- span 
significantly, resulting in a net loss of microglia. A diminished replenishment and increased 
vulnerability of microglia with age (Streit, 2006; Graeber et al., 2010) could compromise the 
microglial tolerance to hypoxia even further. Our observations support this, as the drop in the 
number of microglia was more severe in old (14 months) than in young (8 months) animals, 
and slightly more aggravated in transgenic animals than in wild- type controls.  
It is also worth considering the length of the microglia- activating stimulus, in our case long- 
term hypoxia. There is evidence, that long periods of activation, i.e. over- activation, lead to 
microglial degeneration, with subsequent consequences on brain function (Graeber et al., 
2010). The illustration in Fig. D03 comes from the same source. In vitro experiments revealed 
that over- activation triggers apoptosis (Liu et al., 2001). Another group presented similar 
results (Polazzi et al., 2006). This is interpreted, in that the microglia cell tries to limit 
bystander injury to neurons and other structures which would result from excessive activation 
and proinflammatory factor shedding. Degenerating microglia are also known to be heavily 
increased in AD (Graeber et al., 2010). 
To summarize, there is a distinction to be made between short- and long- term activation of 
microglia. In the short- term, activated microglia provide support to neurons in distress. 
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However, long- term activation leads to microglial apoptosis and later neurodegeneration 
(Fig. D03). In this framework, the different microglial behaviours observed in the 
experiments (histology and cell culture) can be explained by the different length of the 
hypoxic stimulus and the subsequent length of microglial activation. In the short- term, 
microglial cells are activated, but do not diminish. In the long- term, microglial cells undergo 
apoptosis, which is aggravated by the presence of A!- toxicity. 
 
 
 
Fig. D03: Illustration of acute and chronic microglial activation, and the different paths this activation leads to. 
Note that in the case of over- activation, microglia undergo apoptosis potentially to limit collateral damage to 
neurons and other structures, that are not as easily replaceable. Figure adopted from Graeber et al.. 
 
2.  Second, the decrease in microglial number could be due to a lower rate of microglial 
 replacement as a consequence of the hypoxic stimulation. As described in the 
introduction, microglial cells are believed to be a long- lived population of tissue 
macrophages (Ransohoff et al., 2009). Under inflammatory conditions, peripheral cells can 
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infiltrate the central nervous system (CNS), and replace or support microglia in their function 
(Graeber et al., 2010). However, caution is necessary when interpreting these findings: The 
properties of one species do not translate simply into another one. For example, infiltration of 
the CNS after peripheral nerve axotomy does occur in mice, but not in rats (Raivich et al., 
1998). In humans, migration across the blood brain barrier is a highly complex issue 
(Larochelle et al., 2011), and differences between rodents and humans are to be expected. 
Various studies have been carried out that examined infiltration to the CNS in AD. Khoury et 
al. found that microglia originate in bone marrow and migrate into the CNS via blood and 
CCR2, which is a chemokine receptor that mediates migration at the blood brain barrier (El 
Khoury et al., 2008). Lower migration was associated with higher levels of A!- protein. 
Another group found immigrating Th2- cells beneficial (Cao et al., 2009). A recent study 
showed that neither microglia nor bone- marrow derived phagocytes altered AD progression. 
But restricting CCR2- deficiency to perivascular myeloid cells, another type of macrophage, 
did affect vascular A!- depositions, but not parenchymal ones (Mildner et al., 2011). This 
contradicts findings of lower A!- levels after immigration of bone- marrow derived 
macrophages (Simard et al., 2006). It can be seen that migration of peripheral cells into the 
CNS is far from understood: It is not agreed upon, to which extend it does take place under 
physiologic conditions. It is unclear, how translatable results are from one species to another. 
And the migration that does take place seems to be diverse and its effects will depend on the 
affected subpopulation of migrating cells, such as microglia or periventricular macrophages. 
This dynamic is further illustrated by Fig. D04.  
It is hypothesized, that the long- term hypoxic stimulus causes a different migration dynamic, 
possibly through alteration of the blood brain barrier, that could lead to less entry of the brain 
from the periphery and little replacement of resident microglia. This, together with a higher 
microglial loss under the stressors at play, could explain the shrinking of the microglia 
population. Furthermore, the high hematocrit (HCT) as a consequence of the hypoxic 
treatment changes the physical properties of the blood; it "thickens" so to speak. This could 
further prevent sufficient migration of cells into the brain. 
Summarizing the two possible explanations, the microglia population could have shrunk due 
to an increased rate of cell death or alternatively due to less replacement, or both combined.  
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Fig. D04: Dynamics of cellular infiltration of the brain after stroke. Illustration adopted from Weinstein et al.  
 
4.5 Summary 
Our results demonstrate that long- term exposure to hypoxia significantly reduces the number 
of microglia. The reduced number results in significantly reduced plaque occupancy and 
compromizes the function of microglia to confront A!- plaques. The A!1-42 load, however, 
is not affected. On the other hand, A! shows an increased trend towards oligomer formation. 
A variety of possible explanations to these phenomena, that in our opinion deserve further 
investigation, has been presented. 
 
5. Future research 
There are several lines of investigation (A to E) that promise further insight and clarification 
in the disputed field of AD. 
 
A: Our findings should be supplemented with behavioural tests and the assessment of markers 
of neuronal damage.  
 
B: Does AD alter, quantitatively or qualitatively, the response to hypoxia, e.g. angiogenesis? 
The speed and quality of angiogenesis and the regulation of blood homeostasis (e.g. HCT) 
should be assessed with a longitudinal study with multiple time points of wild- type vs. 
transgenic animals under hypoxia. 
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C: Does hypoxia systematically change the A!- protein conformation and accumulation 
properties? Experiments that measure oligomer quantity according to molecular weight by 
native Western blotting should be undertaken. Also, the plaque distribution and plaque 
properties (i.e. diffuse or solid deposition) should be assessed using histology. 
 
D: Further investigation of A!- clearance mechanisms under hypoxia, especially microglia- 
independent ones, needs to be done. Attention should be focused on the blood- brain barrier 
and receptors such as RAGE. However, approaches that create a "leaky" blood brain barrier 
by radiation need to be assessed with caution. 
 
E: The same model should be reproduced with localized tissue hypoxia. This could be 
achieved through in vivo ligation of specific vessels, i.e. induced strokes, by laser. It would 
then be possible to clear any disturbing effects that a whole- body scale adaption to hypoxia 
has on the investigated issue.  
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Clinical findings have linked multiple risk factors and associated pathologies to Alzheimer's 
disease (AD). Amongst them are vascular risk factors such as hypertension and pathologies 
such as stroke. Coexistence of AD and these associated pathologies worsenes dementia, the 
clinical hallmark of the disease, as compared to pure AD. One general common denominator 
of these associated pathologies is the presence of hypoxic tissue conditions. It was asked the 
question, whether there exists a mutual, causal interaction between hypoxia and AD 
pathology, that could explain the clinical observations. Alternatively, the worsened clinical 
state of multiple brain pathologies could "simply" be the consequence of multimorbidity, i.e. 
accumulated disease load, without any causal interaction between the constituents.  
To approach this question whether hypoxia influences AD progression, use was made of a 
murine animal model of AD (transgenic mice: APPswe, PSEN1dE). Animals of two ages (8 
and 14 months, "young" and "old" respectively) and two genotypes (transgenic and wild- 
type) were either treated under hypoxia or normoxia, corresponding to 8% and 21% oxygen, 
for 20 consecutive days. The resulting changes in the brain were assessed with a variety of 
techniques, namely by histology, ELISA, dot and Western blotting. Additional experiments in 
primary cell cultures were performed.  
Animals exposed to hypoxia showed an increased hematocrit (HCT), weight loss, reactive 
angiogenesis, but no infarctions. This illustrates that our hypoxic treatment put significant 
stress on the animals, without causing major pathologies. 
A large number of variables exists that could potentially be measured to assess the effect of 
hypoxia on AD. The focus was put on three of them: First, there is the A!1-42- protein, 
known to be the A!- isoform associated with the most detrimental disease progression. In 
AD, the self-combinatory Amyloid- beta peptide (A!) accumulates in the brain in so- called 
plaques, which is a main histologic finding of the disease. Its quantity was determined 
through histology and ELISA.  
Secondly, it was attempted to estimate the structural quality of the A!- protein by assessing 
the amount of A!- oligomers present. A!- protein does self- accumulate in various grades of 
complexity, i.e. as monomer, oligomer or fibril. Since oligomers are known to be the most 
neurotoxic "species" of the A!- protein, it was hypothesized that under hypoxic treatment 
their quantity could increase.  
And third, the organism's response to the A!- protein stimulus was investigated. Microglial 
cells have been described as the first cells to encounter the A!- protein "threat" in the shape 
of plaques, i.e. A!- protein aggregates. They then try to encapsulate and subsequently degrade 
them. Therefore, the attention was put on this cellular population. 
It was asked whether hypoxia could change the A!- protein quantity in the brain. This was 
assessed in two ways: First histologically, by staining for A!- protein depositions and 
quantifying them. Second, an ELISA was performed. Our findings state that hypoxic 
treatment does not alter the A!1-42 protein load in the brain, neither in young nor old 
animals, as assessed by histology and by total ELISA quantification of A!1-42 protein. 
Since hypoxia did not alter the quantity of the A!- protein, it was asked whether it influenced 
it qualitatively? If hypoxia increased oligomer formation, this change in the spectrum of the 
A!- species could, without any change in total A!- protein load, lead to increased 
neurotoxicity in animals under hypoxia. Initial experiments showed that oligomer formation 
in the brain seems to increase. However, this was not statistically significant and future 
experiments are necessary to evaluate this hypothesis further. 
It was then asked, whether hypoxia alters the cellular response to the protein. The total 
number of microglia in the hippocampal dentate gyrus, our structure of interest for practical 
purposes, and, it can be argued, by extension the brain, changes dynamically with various 
factors. First, transgenic animals present an increase in microglia. Second, microglia increase 
with age. Third, microglia decrease under hypoxia, but only do so significantly in old animals.  
Next, a parameter called "plaque occupancy" was coined to assess the microglia function to 
confront A!- plaques. Plaque occupancy is defined as the number of microglia in spatial 
proximity to one square millimeter of A!- plaque. This means, that microglia restricting one 
plaque are counted, and then normalized to this plaque's area. It was hypothesized that 
hypoxia would decrease plaque occupancy. Indeed, plaque occupancy roughly halved under 
hypoxia. 
 
Summarizing, our results demonstrate that long- term exposure to hypoxia significantly 
reduces the number of microglia. The reduced number results in significantly reduced plaque 
occupancy and compromizes the function of microglia to confront A!- plaques. The A!1-42 
load, however, is not affected. On the other hand, A! shows an increased trend towards 
oligomer formation. A variety of possible explanations to these phenomena have been 
presented, that in our opinion deserve further investigation. 
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